JP5212837B2 - Permselective hollow fiber membrane - Google Patents
Permselective hollow fiber membrane Download PDFInfo
- Publication number
- JP5212837B2 JP5212837B2 JP2009233985A JP2009233985A JP5212837B2 JP 5212837 B2 JP5212837 B2 JP 5212837B2 JP 2009233985 A JP2009233985 A JP 2009233985A JP 2009233985 A JP2009233985 A JP 2009233985A JP 5212837 B2 JP5212837 B2 JP 5212837B2
- Authority
- JP
- Japan
- Prior art keywords
- hollow fiber
- fiber membrane
- film
- membrane
- nozzle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Artificial Filaments (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Description
本発明は、セルロースアセテート系ポリマーからなる中空糸膜に関するものである。詳しくは、本発明は、少なくとも中空糸膜の内表面側に薄い分離活性層(緻密層)を形成し、内表面側から外表面側に向かう方向に特定の粗密構造を与えることによって、従来にない高い溶質透過性とろ過安定性、高強度を付与した中空糸膜に関するものである。 The present invention relates to a hollow fiber membrane made of a cellulose acetate polymer. Specifically, the present invention has been conventionally achieved by forming a thin separation active layer (dense layer) at least on the inner surface side of the hollow fiber membrane and providing a specific dense structure in the direction from the inner surface side to the outer surface side. The present invention relates to a hollow fiber membrane having high solute permeability, filtration stability and high strength.
中空糸膜は、逆浸透から精密濾過に至る分野において従来より広く使用されている。特に腎不全患者の血液を浄化するために、現在では中空糸型モジュールがよく使用されている。これは筐体の中に分離膜、例えば、中空糸膜を多数本収納し、その中空部に患者の血液を流し、外部、即ち中空糸膜間隙部に透析液を流して、中空糸膜壁を介して透析することによって、血液中の老廃物を除去したり、電解質濃度を是正するとともに、中空糸膜内外に圧力差を与えて濾過によって血液中の中分子量物質や余剰水分を除去するものである。更に、血液中から血漿のみを分離し、あるいは、その血漿の中から特定成分を除去して自己免疫疾患などを治療するために、中空糸膜が使用されることもある。また、最近になってタンパク透過性血液透析やタンパク透過性血液濾過透析に中空糸膜を用いることによって治療効果が得られることが確認されている。 Hollow fiber membranes have been widely used in the field from reverse osmosis to microfiltration. Currently, hollow fiber modules are often used to purify the blood of patients with renal failure. This is because the housing contains a large number of separation membranes, for example, hollow fiber membranes, the patient's blood is flowed through the hollow portions, and the dialysate is flowed into the outside, that is, the hollow fiber membrane gaps. By removing the waste products in the blood by dialysis through the filter, the electrolyte concentration is corrected, and the medium molecular weight substances and excess water in the blood are removed by filtration by applying a pressure difference inside and outside the hollow fiber membrane. It is. Furthermore, a hollow fiber membrane may be used to separate only plasma from blood or remove specific components from the plasma to treat autoimmune diseases and the like. Recently, it has been confirmed that a therapeutic effect can be obtained by using a hollow fiber membrane for protein permeable hemodialysis or protein permeable hemofiltration dialysis.
ところで、近年、透析患者の長期合併症と関連し、透析アミロイドーシスの原因物質と考えられるβ2ミクログロブリン(β2MG、分子量:11,800)、掻痒感、高脂血症と関係すると考えられる副甲状腺ホルモン(分子量:約9,500)、貧血に関与する赤芽球抑制因子、関節痛、骨痛に係わると考えられる分子量2〜4万の物質、たとえばα1マイクログロブリン(α1MG、分子量:33,000)など、比較的中高分子量領域の有害物質の除去の必要性が叫ばれている。一方、人体にとって有用なアルブミン(分子量:66,000)の損失は極力避けなければならない。すなわち、分子量2〜4万の物質の透過性に優れ、分子量6万以上の物質の阻止性のよい分画分子量のシャープカット性の良好な選択透過性膜が望まれている。 By the way, in recent years, parathyroid hormone is considered to be related to β2 microglobulin (β2MG, molecular weight: 11,800), pruritus, and hyperlipidemia, which are related to long-term complications of dialysis patients and are considered as causative substances of dialysis amyloidosis. (Molecular weight: about 9,500), erythroblast-inhibiting factor involved in anemia, arthralgia, substance having a molecular weight of 20,000 to 40,000, for example, α1 microglobulin (α1MG, molecular weight: 33,000) The necessity of removing toxic substances in the relatively high molecular weight region is screamed. On the other hand, the loss of albumin (molecular weight: 66,000) useful for the human body must be avoided as much as possible. That is, there is a demand for a selectively permeable membrane excellent in the permeability of a substance having a molecular weight of 20,000 to 40,000 and having a high molecular weight of 60,000 or more and having a good molecular weight and sharp-cut property.
血液処理用の中空糸膜は、前述のように、目的に応じて特定の物質を選択的に透過させなければならず、その性能は、中空糸膜の素材、膜構造、ポロシティ(孔の大きさ、数など)、膜厚などによって決定される。 As described above, a hollow fiber membrane for blood treatment must selectively permeate a specific substance depending on the purpose, and its performance depends on the material of the hollow fiber membrane, the membrane structure, and the porosity (pore size). And the number) and the film thickness.
前述の膜性能を得るには、出来るだけ高い透水率(UFR)を有する中空糸膜が必要であり、従来から、ポリスルホンなどの合成高分子では、例えば特許文献1、2に見られるように、比較的前記要求を満たしたものが得られている。しかし、これらの特許文献にはα1−マイクログロブリンの除去効率の記載は見られない。 In order to obtain the above-mentioned membrane performance, a hollow fiber membrane having as high a water permeability (UFR) as possible is necessary. Conventionally, synthetic polymers such as polysulfone, as seen in Patent Documents 1 and 2, for example, The thing which comparatively satisfy | filled the said request | requirement is obtained. However, these patent documents do not describe the removal efficiency of α1-microglobulin.
また、特許文献3に見られるように、中空糸膜を湿式紡糸するときの内液に流動パラフィン、高級アルコール、イソプロピルミリステートなど、セルロースアセテート系ポリマーに対し凝固性のない(低い)ものを使用する場合には、前述のような非対称構造を得ることができなかった。 In addition, as shown in Patent Document 3, the liquid used when wet spinning a hollow fiber membrane uses a liquid paraffin, higher alcohol, isopropyl myristate, or the like that has no solidification (low) for cellulose acetate polymers. In this case, the asymmetric structure as described above could not be obtained.
内面に緻密層を有する非対称構造を有するセルローストリアセテート膜が、例えば、特許文献4、5に開示されている。これらの特許文献では、内液に凝固性のある水溶液を使用し、従来、合成高分子で実現されていた2層または多層構造の膜構造を得ることができている。しかし、内液の水溶液濃度を下げると曳糸性が低下するため、中空糸膜製造の安定化が大変難しいことが記載されている。このように、血液透析器として使用するためには中空糸膜の生産性を確保するだけでなく、モジュールの組立て性も合わせて確保しないとトータルの生産性は向上しない。したがって、全体の生産性を向上させるためには改良の余地がある。 For example, Patent Documents 4 and 5 disclose cellulose triacetate films having an asymmetric structure having a dense layer on the inner surface. In these patent documents, an aqueous solution having a solidification property is used as an internal solution, and a two-layer or multi-layer film structure which has been conventionally realized with a synthetic polymer can be obtained. However, it is described that it is very difficult to stabilize the hollow fiber membrane production because the spinnability is lowered when the aqueous solution concentration of the internal solution is lowered. Thus, in order to use as a hemodialyzer, not only the productivity of the hollow fiber membrane is ensured, but the total productivity cannot be improved unless the assembly property of the module is also secured. Therefore, there is room for improvement in order to improve the overall productivity.
また、膜内壁部表面近傍層における微細孔の孔径が500nm以下であり、膜厚方向断面に分布する微細孔の孔径分布において少なくとも1つ以上の極大孔径を有し、その極大孔径が膜内壁部表面近傍層における孔径の1.2倍以上の大きさでありかつ膜外壁部表面近傍層の孔径が膜内壁部表面近傍層の孔径の0.6倍以上1.2倍未満の大きさを有する中空糸分離膜が開示されている。(特許文献6参照)。しかし、この特許文献に記載の中空糸膜は、透析液から血液へのエンドトキシンの逆流入を防ぐことを目的に膜外壁部表面近傍層の孔径を比較的小さくしているためか、透水性が低すぎてβ2MGに代表される低分子タンパクの除去性を高めるのは困難である。 In addition, the pore diameter of the micropores in the layer near the surface of the inner wall of the membrane is 500 nm or less, and has at least one maximum pore size in the pore size distribution distributed in the cross section in the film thickness direction. The pore diameter of the layer near the surface is 1.2 times or more and the pore diameter of the layer near the surface of the outer membrane wall is 0.6 or more and less than 1.2 times the pore diameter of the layer near the membrane inner wall surface. A hollow fiber separation membrane is disclosed. (See Patent Document 6). However, the hollow fiber membrane described in this patent document has a water permeability that may be because the pore diameter of the layer near the surface of the outer wall of the membrane is relatively small for the purpose of preventing reverse entry of endotoxin from the dialysate into the blood. It is too low to increase the removability of low molecular weight proteins typified by β2MG.
また、セルロース誘導体からなり、少なくとも内面に緻密層、その外層に多孔層を有する中空糸膜およびその製造方法が開示されている。(特許文献7〜10参照)。しかし、これらの特許文献に記載される中空糸膜は、膜強度を確保するために膜厚を厚くしており、中空糸膜タイプのモジュールのメリットであるコンパクト性が損なわれている。 Also disclosed is a hollow fiber membrane comprising a cellulose derivative and having a dense layer at least on the inner surface and a porous layer on the outer layer, and a method for producing the same. (See Patent Documents 7 to 10). However, the hollow fiber membranes described in these patent documents have a large thickness in order to ensure the membrane strength, and the compactness that is the merit of the hollow fiber membrane type module is impaired.
また、特許文献11には、同様にセルロースアセテート系ポリマーからなる非対称構造を有する中空糸膜に関する技術が開示されている。この特許文献に記載の中空糸膜は、膜厚が薄い割には膜強度が高く、またβ2MGの透過性も比較的高くなってはいるが、ダイアライザー機能分類のIV型までの性能を達成しているに過ぎない。 Patent Document 11 discloses a technique related to a hollow fiber membrane having an asymmetric structure made of a cellulose acetate polymer. Although the hollow fiber membrane described in this patent document has a high membrane strength for a thin film thickness and a relatively high β2MG permeability, it achieves performance up to type IV of the dialyzer function classification. It ’s just that.
本発明は、このような従来技術の問題点を解決することを目的とするものであり、具体的には、中空糸膜の膜厚方向に特定の粗密構造を与え、高い透水性および分子量分画特性、溶質透過性を付与するものである。特に、本発明は、血液透析や血液透析ろ過において、β2MG〜α1MGサイズの有害物質の除去性とアルブミンなどの有用物質の流出阻止性を高めることが可能な中空糸膜を提供することを目的とするものである。 The present invention aims to solve such problems of the prior art. Specifically, the present invention provides a specific dense structure in the film thickness direction of the hollow fiber membrane, and has high water permeability and molecular weight content. It imparts image characteristics and solute permeability. In particular, it is an object of the present invention to provide a hollow fiber membrane that can enhance removal of harmful substances having a size of β2MG to α1MG and outflow prevention of useful substances such as albumin in hemodialysis and hemodiafiltration. To do.
本発明者は、上記目的を達成するために鋭意検討した結果、遂に本発明の完成に至った。 As a result of intensive studies to achieve the above object, the present inventors have finally completed the present invention.
即ち、本発明は、以下の(1)〜(4)の構成を有するものである。
(1)セルロースアセテート系ポリマーからなる非対称構造を有する中空糸膜であって、中空糸膜を走査型電子顕微鏡を用いて倍率10000倍で観察したとき、
(a)内表面における300nm以上の孔の存在率が0.5%以下であること、
(b)中空糸膜の断面において、内表面から膜厚の20%までの領域の開孔率が0.1〜5%、外表面から膜厚の20%までの領域の開孔率が22〜30%、それ以外の中間部の領域の開孔率が10〜20%であること、
中空糸膜を用いて内径基準による膜面積が1.5m 2 のモジュールを作製すると、血液流路側にヒトβ2MG(分子量18,000)を0.05〜0.1mg/lの濃度になるように添加した総タンパク質濃度が6.5±0.5g/dl、37℃に保温したACD添加牛血漿を流量200ml/min、透析液側に透析液を500ml/min、ろ過流量15ml/minで流した際に、透析開始後60分時点および240分時点のβ2MGのクリアランスが65ml/min以上であること、及び
内表面から外表面に向かって当初開孔率が増大し、そのまま中間部を過ぎて外表面近傍まで開孔率がほぼ一定で推移し、外表面付近で再度開孔率が増大するような構造を有すること
を特徴とする中空糸膜。
(2)内表面における平均面粗さが10nm以下であることを特徴とする(1)に記載の中空糸膜。
(3)内表面の開孔率が0.5%以下であることを特徴とする(1)または(2)に記載の中空糸膜。
(4)製膜原液と内液を二重管状ノズルから吐出した後、エアギャップを通過させてから凝固浴で凝固させる工程を含む(1)〜(3)のいずれかに記載の中空糸膜の製造方法において、
(a)製膜原液が、セルロースアセテート系ポリマー、前記ポリマーの溶剤および非溶剤からなること、
(b)内液の水の含有量が95重量%以上100重量%以下であること、
(c)ノズル部での製膜原液の温度が70℃以上110℃以下、内液の温度が0℃以上40℃以下であること、
(d)凝固浴の溶剤濃度が40重量%以上60重量%以下であること、
(e)ノズルドラフト比が0.9〜1.3であること、
(f)ノズルのスリット外径が220〜330μm、スリット内径が150〜270μmであること、
を特徴とする方法。
That is, the present invention has the following configurations (1) to (4).
(1) A hollow fiber membrane having an asymmetric structure made of a cellulose acetate polymer, wherein the hollow fiber membrane is observed at a magnification of 10,000 using a scanning electron microscope.
(A) The presence rate of pores of 300 nm or more on the inner surface is 0.5% or less ,
(B) In the cross section of the hollow fiber membrane, the porosity of the region from the inner surface to 20% of the film thickness is 0.1 to 5%, and the porosity of the region from the outer surface to 20% of the film thickness is 22 ~ 30%, the porosity of the other intermediate region is 10-20%,
When a module having a membrane area of 1.5 m 2 based on the inner diameter standard is produced using a hollow fiber membrane , human β2MG (molecular weight 18,000) is adjusted to a concentration of 0.05 to 0.1 mg / l on the blood channel side. The total protein concentration added was 6.5 ± 0.5 g / dl, ACD-added bovine plasma kept at 37 ° C. was flowed at a flow rate of 200 ml / min, dialysate was flowed to the dialysate side at 500 ml / min, and the filtration flow rate was 15 ml / min. The clearance of β2MG at the time of 60 minutes and 240 minutes after the start of dialysis is 65 ml / min or more, and
A structure in which the initial hole area ratio increases from the inner surface toward the outer surface, the hole area ratio remains almost constant from the middle part to the vicinity of the outer surface, and the hole area ratio increases again near the outer surface. the hollow fiber membrane according to claim <br/> to have.
(2) The hollow fiber membrane according to (1), wherein the average surface roughness on the inner surface is 10 nm or less.
(3) The hollow fiber membrane according to (1) or (2), wherein the porosity of the inner surface is 0.5% or less.
(4) The hollow fiber membrane according to any one of (1) to (3), including a step of discharging the membrane-forming stock solution and the internal solution from a double tubular nozzle and then allowing the membrane to pass through an air gap and then coagulating in a coagulation bath. In the manufacturing method of
(A) The film-forming stock solution comprises a cellulose acetate polymer, a solvent of the polymer and a non-solvent,
(B) The content of water in the internal solution is 95% by weight or more and 100% by weight or less,
(C) The temperature of the film-forming stock solution at the nozzle part is 70 ° C. or higher and 110 ° C. or lower, and the temperature of the internal solution is 0 ° C. or higher and 40 ° C. or lower,
(D) the solvent concentration of the coagulation bath is 40 wt% or more and 60 wt% or less;
(E) the nozzle draft ratio is 0.9 to 1.3;
(F) The nozzle slit outer diameter is 220 to 330 μm, and the slit inner diameter is 150 to 270 μm.
A method characterized by.
本発明の中空糸膜は、少なくとも内表面側に緻密層を有する、いわゆる非対称構造膜であるが、膜断面中間部を均質構造に近い構造とし、また内表面の平滑性や開孔率を適正化したことによって、非常に薄膜でありながら中空糸膜の強度と、溶質除去の安定性、有用タンパクの漏出の抑制を高い次元で両立している。そのため血液透析だけでなく血液透析ろ過や血液ろ過にも好適に使用できるという効果を奏する。 The hollow fiber membrane of the present invention is a so-called asymmetric structure membrane having a dense layer at least on the inner surface side. However, the intermediate portion of the membrane has a structure close to a homogeneous structure, and the inner surface is smooth and has an appropriate porosity. As a result, the strength of the hollow fiber membrane, the stability of solute removal, and the suppression of leakage of useful proteins are compatible at a high level even though it is a very thin film. Therefore, there is an effect that it can be suitably used not only for hemodialysis but also for hemodiafiltration and blood filtration.
従来、分離膜としては、一方の膜表面から他方の膜表面にかけて膜構造がほぼ均一である均質構造膜や、一方の表面に緻密層を有し他方の表面に向かって次第に孔径が拡大するような非対称構造膜が主流である。血液浄化用の中空糸膜において、内表面側に薄い緻密層を有し、外表面側に向かって細孔径が拡大するような非対称構造の場合、薄い緻密層のみが除去物質の透過に寄与し、緻密層以外の部分(支持層)は細孔径が大きいために透過の抵抗にならず、β2ミクログロブリン(β2MG)に代表される低分子タンパクの除去性を高めるうえで有利とされている。支持層は、主に膜の強度を保持する役割を担うものである。しかし、血液浄化膜において、緻密層の厚みは通常0.1〜数μm程度と非常に薄くしているために、細孔分布の影響を吸収しきれず、分画性(β2MGの除去とアルブミンの漏出抑制)を高めるうえで限界があった。 Conventionally, as a separation membrane, a homogeneous structure membrane having a substantially uniform membrane structure from one membrane surface to the other membrane surface, or a dense layer on one surface so that the pore diameter gradually increases toward the other surface. Asymmetric structure films are the mainstream. In a hollow fiber membrane for blood purification, in the case of an asymmetric structure that has a thin dense layer on the inner surface side and the pore diameter increases toward the outer surface side, only the thin dense layer contributes to the permeation of the removed substance. The portion other than the dense layer (support layer) is not advantageous in permeation due to its large pore size, and is advantageous for enhancing the removability of low molecular weight proteins typified by β2 microglobulin (β2MG). The support layer mainly plays a role of maintaining the strength of the film. However, in the blood purification membrane, the thickness of the dense layer is usually very thin, about 0.1 to several μm, so that the influence of the pore distribution cannot be absorbed, and fractionation (removal of β2MG and albumin) There was a limit in improving leakage control.
本発明の中空糸膜は、内表面側に緻密層を有し、外表面側は内表面側に比較して拡大された孔径を有する点において、いわゆる非対称構造膜に属する。そして、中空糸膜を走査型電子顕微鏡(SEM)を用いて倍率10,000倍で観察したとき、内表面に孔が実質的に観察されない。また、原子間力顕微鏡で膜表面の凹凸を測定した際の基準点に対する全測定点の凹凸の算術平均を表す平均面粗さ(Ra)が10nm以下であることが好ましい。 The hollow fiber membrane of the present invention belongs to a so-called asymmetric structure membrane in that it has a dense layer on the inner surface side and the outer surface side has an enlarged pore diameter compared to the inner surface side. When the hollow fiber membrane is observed at a magnification of 10,000 using a scanning electron microscope (SEM), no pores are substantially observed on the inner surface. Moreover, it is preferable that average surface roughness (Ra) showing the arithmetic average of the unevenness | corrugation of all the measurement points with respect to the reference point at the time of measuring the unevenness | corrugation of the film | membrane surface with an atomic force microscope is 10 nm or less.
孔が実質的に観察されないとは、倍率10,000倍の写真に長径3mm以上の孔、すなわち内表面に300nm以上の孔の存在率が0.5%以下であることを指す。倍率10,000倍で観察した際に孔や凹凸が観察されないのが最も好ましいが、孔の存在率が0.5%以下程度、Ra値が10nm以下であれば実使用において膜の目詰まりやいわゆる2次層の生成を抑え、限外ろ過速度や溶質の分離性能の経時安定性を向上するのに有利である。 The fact that pores are not substantially observed means that the abundance ratio of pores having a major axis of 3 mm or more, that is, pores having a diameter of 300 nm or more on the inner surface is 0.5% or less in a photograph at a magnification of 10,000. Most preferably, no pores or irregularities are observed when observed at a magnification of 10,000 times. However, if the abundance of the pores is about 0.5% or less and the Ra value is 10 nm or less, clogging of the film in actual use This is advantageous in suppressing the generation of so-called secondary layers and improving the temporal stability of ultrafiltration speed and solute separation performance.
さらに、本発明の中空糸膜は、支持層部分の膜構造を仔細に観察すれば、内表面から外表面に向かって当初空孔率が増大し、そのまま中間部を過ぎて外表面近傍まで空孔率がほぼ一定で推移し、外表面付近で再度空孔率が増大するような構造を有する点で従来の非対称構造膜とは異なる。すなわち、内表面側に緻密層を有するということは、内表面の緻密層が分画性(有用物質であるアルブミン等の流出阻止)を規定し、中間層が透過性(β2MGなどの除去)を規定し、その分画性と透過性への寄与は内表面側の緻密層が主、中間部および外表面側の層が従であるということを意味する。血液等の流体を処理する場合、内表面では流体によるせん断力が生じるため、表面への血中タンパク等の堆積を避けやすい。この際、表面に緻密層があることでよりその効果は高くなる。また、この緻密層の背後の部分は、大孔径、大空孔率のスポンジ状支持層となっているほうが、流体の抵抗が低くなり、高透過性を得られやすい点で有利である。しかし、そうすると必要な膜強度を確保するために膜厚を厚くする必要が生じ、中空糸膜タイプのモジュールのメリットであるコンパクト性が損なわれる問題がある。そこで、本発明においては、内表面側に緻密層を設けるだけでなく、膜厚部分の中間部付近の層の孔径や空孔率を除去物質の透過抵抗にならない程度の比較的密な構造とすることによって、膜厚を厚くせずとも高い溶質除去性と強度を確保することが可能となった。 Furthermore, when the membrane structure of the support layer portion is closely observed, the hollow fiber membrane of the present invention increases in the initial porosity from the inner surface to the outer surface, and passes through the intermediate portion as it is to the vicinity of the outer surface. This is different from the conventional asymmetric structure film in that the porosity changes substantially constant and the porosity increases again near the outer surface. That is, having a dense layer on the inner surface side means that the dense layer on the inner surface defines fractionation (preventing the outflow of albumin, which is a useful substance), and the intermediate layer has permeability (removal of β2MG, etc.). The contribution to the fractionation and permeability means that the dense layer on the inner surface side is the main and the intermediate part and the outer surface side are the subordinates. When a fluid such as blood is processed, shearing force due to the fluid is generated on the inner surface, so that it is easy to avoid accumulation of protein in the blood on the surface. At this time, the effect is further enhanced by the presence of the dense layer on the surface. In addition, it is advantageous that the portion behind the dense layer is a sponge-like support layer having a large pore diameter and a large porosity because the fluid resistance is low and high permeability can be easily obtained. However, if it does so, it will be necessary to make a film thickness thick in order to ensure the required film | membrane intensity | strength, and there exists a problem by which the compactness which is the merit of a hollow fiber membrane type module is impaired. Therefore, in the present invention, not only a dense layer is provided on the inner surface side, but also a relatively dense structure in which the pore diameter and porosity of the layer in the vicinity of the middle part of the film thickness portion do not become the permeation resistance of the removed substance. By doing so, it became possible to ensure high solute removal property and strength without increasing the film thickness.
前記したような本発明の中空糸膜の構造は、中空糸膜断面を10,000倍の走査型電子顕微鏡で観察することにより、確認することができる。すなわち、中空糸断面を内側から外側に向けてほぼ均等に5分割し、それぞれ(断面1、2、3、4、5とする)の開孔率を測定した場合に、断面1においては0.1〜5%、断面2〜4においては10〜20%、断面5においては22〜30%である。もちろん、断面1と2または断面4と5の間において、開孔率は不連続に変化するものではなく、中空糸膜の製造条件から見ても開孔率は断面方向において連続的に変化している。しかし、本発明の中空糸膜は、相分離条件を調整することにより、一般的な非対称構造膜のようなリニアなグラジェント構造ではなく、ステップワイズなグラジェント構造を獲得している。このような構造を分離膜に与えることによって、非常に薄膜でありながら高性能と高強度を両立することが可能となった。 The structure of the hollow fiber membrane of the present invention as described above can be confirmed by observing the cross section of the hollow fiber membrane with a scanning electron microscope of 10,000 times. That is, when the cross section of the hollow fiber is divided almost equally into 5 from the inside to the outside and the open area ratio of each (sections 1, 2, 3, 4, 5) is measured, 1 to 5%, 10 to 20% in the cross sections 2 to 4, and 22 to 30% in the cross section 5. Of course, the open area ratio does not change discontinuously between the cross sections 1 and 2 or the cross sections 4 and 5, and the open area ratio changes continuously in the cross section direction even when viewed from the manufacturing conditions of the hollow fiber membrane. ing. However, the hollow fiber membrane of the present invention has acquired a stepwise gradient structure rather than a linear gradient structure like a general asymmetric structure membrane by adjusting the phase separation conditions. By giving such a structure to the separation membrane, it is possible to achieve both high performance and high strength while being a very thin film.
本発明において、血液の流動安定性を確保するためには中空糸膜の内径を150μm以上300μm以下とするのが好ましい。中空糸膜の内径が小さすぎると血流の線速度が高くなるため、血球成分がダメージを受ける可能性がある。逆に、中空糸膜の内径が大きすぎると血液の剪断速度や圧力損失が高まらず、中高分子量物質の透過に寄与するろ過の効果が小さくなり、また不足する膜性能を補うためにモジュール(血液浄化器)のサイズを不必要に大きくしなければならないなど使用の利便性を損なう可能性がある。したがって、中空糸膜の内径は160μm以上280μm以下がより好ましく、170μm以上260μm以下がさらに好ましい。 In the present invention, in order to ensure blood flow stability, the inner diameter of the hollow fiber membrane is preferably 150 μm or more and 300 μm or less. If the inner diameter of the hollow fiber membrane is too small, the blood flow linear velocity increases, and the blood cell component may be damaged. On the other hand, if the hollow fiber membrane is too large in diameter, the blood shear rate and pressure loss will not increase, the filtration effect contributing to the permeation of medium high molecular weight substances will be reduced, and the module (blood There is a possibility that the convenience of use is impaired, for example, the size of the purifier must be increased unnecessarily. Therefore, the inner diameter of the hollow fiber membrane is more preferably 160 μm or more and 280 μm or less, and further preferably 170 μm or more and 260 μm or less.
本発明において、中空糸膜の膜厚は10μm以上30μm未満が好ましい。中空糸膜の膜厚が薄すぎると透過性能は高まるが必要な強度を維持することが困難な場合があり、また膜厚が大きすぎると物質の透過抵抗が大きくなり、除去物質の透過性が不充分となる可能性がある。また、モジュールのサイズを大きくする必要があるなど、使用の利便性を損なう可能性がある。したがって、中空糸膜の膜厚は12μm以上28μm以下がより好ましく、13μm以上26μm以下がさらに好ましい。 In the present invention, the thickness of the hollow fiber membrane is preferably 10 μm or more and less than 30 μm. If the hollow fiber membrane is too thin, the permeation performance will increase, but it may be difficult to maintain the required strength.If the membrane is too large, the permeation resistance of the substance will increase and the permeability of the removed substance will increase. It may be insufficient. In addition, there is a possibility that the convenience of use may be impaired because the size of the module needs to be increased. Therefore, the film thickness of the hollow fiber membrane is more preferably 12 μm or more and 28 μm or less, and further preferably 13 μm or more and 26 μm or less.
本発明の中空糸膜を得るための基本的な製造条件は、特許文献7〜11に記載されるような条件が採用できる。ポリマー、ポリマーの溶剤および非溶剤からなる製膜原液、およびポリマーに対して凝固性のある内液を使用して、二重管状ノズルから同時に吐出し、エアギャップ部を通過させた後、凝固浴に導いて凝固させ、中空糸膜形状を固定する。得られた中空糸膜を洗浄浴にて過剰の溶剤、非溶剤を除去し、膜孔保持剤を細孔内に含浸させた後、乾燥して巻き取る。 As basic production conditions for obtaining the hollow fiber membrane of the present invention, conditions as described in Patent Documents 7 to 11 can be adopted. Using a film-forming stock solution consisting of a polymer, a polymer solvent and a non-solvent, and an internal solution solidifying with respect to the polymer, it is discharged simultaneously from a double tubular nozzle, passed through an air gap, and then coagulated bath To solidify and fix the hollow fiber membrane shape. Excess solvent and non-solvent are removed from the obtained hollow fiber membrane in a washing bath, a membrane pore retainer is impregnated in the pores, and then dried and wound up.
従来の非対称膜を得る方法では、製膜原液の流動性を確保し、所望の性能を得るために、製膜原液の粘度を可紡範囲に調整する必要があった。しかしながら、粘度を調整するために製膜原液中のポリマー濃度を下げることは、結果的に製膜された中空糸膜中のポリマー密度が低くなるため、中空糸膜強度の低下に繋がる。 In the conventional method for obtaining an asymmetric membrane, it is necessary to adjust the viscosity of the film-forming stock solution within the spinning range in order to ensure the fluidity of the film-forming stock solution and obtain the desired performance. However, decreasing the polymer concentration in the membrane forming stock solution to adjust the viscosity results in a decrease in the polymer density in the formed hollow fiber membrane, leading to a decrease in the strength of the hollow fiber membrane.
一般的に、ポリマー濃度を高くすると、製膜原液の粘度が高まり流動性が低下するため、ノズル温度を比較的高く設定し、製膜原液の流動性を確保する必要がある。ノズル温度を高くすること自体は特に困難性はないが、中空糸膜内表面に緻密層を形成するためには内液として水溶液を用いる必要があり、該水溶液の沸騰を防ぐようにノズル温度を設定する必要がある。そこで、本発明者らは、製膜原液の流動性を確保しつつ、内液の沸騰を防ぐために鋭意検討した結果、製膜原液と内液とをノズルより吐出する直前まで別々に温度コントロールする手段を見出した。具体的には、後述するような手段を用いることで内液の沸騰を防ぎながら製膜原液の流動性を確保することに成功している。 Generally, when the polymer concentration is increased, the viscosity of the film-forming stock solution is increased and the fluidity is lowered. Therefore, it is necessary to set the nozzle temperature relatively high to ensure the fluidity of the film-forming stock solution. Increasing the nozzle temperature itself is not particularly difficult, but in order to form a dense layer on the inner surface of the hollow fiber membrane, it is necessary to use an aqueous solution as the internal solution, and the nozzle temperature is set to prevent boiling of the aqueous solution. Must be set. Accordingly, as a result of intensive investigations to prevent the boiling of the internal solution while ensuring the fluidity of the film forming stock solution, the present inventors separately control the temperature until immediately before discharging the film forming stock solution and the internal solution from the nozzle. Found a means. Specifically, it has succeeded in securing the fluidity of the film-forming stock solution while preventing the boiling of the internal solution by using the means described later.
本発明では、血液浄化用の分離膜の素材として、セルロースアセテート系ポリマーを用いる。セルロースアセテート系ポリマーは、水酸基がある程度キャップされており、補体活性の抑制や血液のクロッティングの無い返血性の良さといった血液適合性に優れており、血液浄化用途に好適である。 In the present invention, a cellulose acetate polymer is used as a material for a separation membrane for blood purification. Cellulose acetate polymers are capped with hydroxyl groups to some extent, have excellent blood compatibility such as suppression of complement activity and good blood return without blood clotting, and are suitable for blood purification applications.
セルロースアセテート系ポリマーとしては、例えば、ダイセル化学工業社よりL−20、30、40、50、70、LT−35、55、105など酢化度、重合度の異なる種々のセルロースアセテート系ポリマーが市販されている(表1参照)。ノズルブロックを加工すれば、このような高粘度のポリマーをポリマー濃度15%超で用いても紡糸が可能であり、中空糸膜強度を確保することは可能である。しかし、さらなる中空糸膜性能の向上と紡糸安定性、モジュール生産性の向上を両立するために、6%粘度が140mPa・s超200mPa・s未満という比較的低粘度のセルロースアセテート系ポリマーを用いることを検討した。その結果、比較的低粘度のポリマーを用い、紡糸原液中のポリマー濃度をさらに高めることにより、中空糸膜強度の確保および膜性能の向上、それらのバランスの最適化を図ることが可能となった。本発明において、中空糸膜の性能と膜の強度をバランスさせるためには、製膜原液中のセルロースアセテート系ポリマー濃度を16質量%以上25質量%以下に設定するのが好ましく、17質量%以上23質量%以下がより好ましい。 As the cellulose acetate polymer, for example, various cellulose acetate polymers having different degrees of acetylation and polymerization such as L-20, 30, 40, 50, 70, LT-35, 55, 105 are commercially available from Daicel Chemical Industries. (See Table 1). If the nozzle block is processed, spinning can be performed even if such a high-viscosity polymer is used at a polymer concentration exceeding 15%, and the strength of the hollow fiber membrane can be ensured. However, in order to achieve further improvements in hollow fiber membrane performance, spinning stability, and module productivity, a relatively low viscosity cellulose acetate polymer having a 6% viscosity of over 140 mPa · s and less than 200 mPa · s should be used. It was investigated. As a result, it became possible to secure the strength of the hollow fiber membrane, improve the membrane performance, and optimize the balance by using a relatively low viscosity polymer and further increasing the polymer concentration in the spinning dope. . In the present invention, in order to balance the performance of the hollow fiber membrane and the strength of the membrane, the concentration of the cellulose acetate polymer in the membrane forming stock solution is preferably set to 16% by mass or more and 25% by mass or less, and preferably 17% by mass or more. 23 mass% or less is more preferable.
本発明において、セルロースアセテート系ポリマーの酢化度は53〜62%であることが好ましい。ここで、酢化度はセルロース中の水酸基の酢酸基置換度を表す。酢化度が低すぎると、ポリマー鎖中に水酸基が多くなるため、ポリマーと血液とが接触した際に補体が活性化しやすくなるなど生体適合性の面で不利になることがある。また、酢化度の理論上限は62.5%であるが、酢化度が高すぎると溶解性や成型性が低下する可能性がある。したがって、セルロースアセテート系ポリマーの酢化度は61.5%以下がより好ましい。酢化度が低いほどポリマーの溶解性や成形性はよくなるが、水酸基が増えるに従い補体活性に代表される血液適合性は低下する傾向にある。したがって、酢化度は55%以上がより好ましく、58%以上がさらに好ましい。 In the present invention, the acetylation degree of the cellulose acetate polymer is preferably 53 to 62%. Here, the degree of acetylation represents the degree of acetate group substitution of hydroxyl groups in cellulose. If the degree of acetylation is too low, the number of hydroxyl groups in the polymer chain increases, which may be disadvantageous in terms of biocompatibility such that complements are easily activated when the polymer comes into contact with blood. Moreover, although the theoretical upper limit of the acetylation degree is 62.5%, if the acetylation degree is too high, solubility and moldability may be lowered. Therefore, the acetylation degree of the cellulose acetate polymer is more preferably 61.5% or less. The lower the degree of acetylation, the better the solubility and moldability of the polymer, but the blood compatibility represented by complement activity tends to decrease as the number of hydroxyl groups increases. Therefore, the acetylation degree is more preferably 55% or more, and further preferably 58% or more.
本発明において、前記セルロースアセテート系ポリマーを溶剤、非溶剤に溶解して製膜原液を調製する。溶剤としては、N−メチルピロリドン、ジメチルホルムアミド、ジメチルアセトアミド、ジメチルスルホキシドなどを使用するのが好ましい。これらの溶媒は水と良好な相溶性を有する。また、非溶剤としては、エチレングリコール、トリエチレングリコール、ポリエチレングリコール200、400、グリセリン、プロピレングリコール、アルコール類などが挙げられ、それぞれ単独でも混合して用いてもよい。溶剤としてN−メチルピロリドン(NMP)、非溶剤としてトリエチレングリコール(TEG)を用いる場合には、セルロースアセテート系ポリマー/NMP/TEG=16〜25/49〜77/7〜26の質量比率で混合して用いるのが好ましい。 In the present invention, the cellulose acetate polymer is dissolved in a solvent and a non-solvent to prepare a film forming stock solution. As the solvent, it is preferable to use N-methylpyrrolidone, dimethylformamide, dimethylacetamide, dimethylsulfoxide, or the like. These solvents have good compatibility with water. Examples of the non-solvent include ethylene glycol, triethylene glycol, polyethylene glycol 200 and 400, glycerin, propylene glycol, alcohols, and the like, and each may be used alone or in combination. When N-methylpyrrolidone (NMP) is used as a solvent and triethylene glycol (TEG) is used as a non-solvent, mixing is performed at a mass ratio of cellulose acetate polymer / NMP / TEG = 16-25 / 49-77 / 7-26. And preferably used.
本発明の中空糸膜は、上述したように非対称構造膜でありながら従来にないほど膜厚を薄くすることができ、除去物質の透過抵抗をできるだけ小さくするよう配慮している。加えて、除去物質が血液から透析液側に移動する際の中空糸膜の入口といえる内表面の平滑性を高めることによって2次層の形成や細孔の目詰まりを抑制する配慮をしている。すなわち、内表面の平滑性を高めるためには、製膜原液をノズルより吐出した後、外乱の影響を受ける前に内表面を素早く凝固(固定)させ、過剰に相分離を進行させないこと、凝固中および凝固した後の内表面に延伸を掛けるなどの外力を与えないこと、中空糸膜構造が固定した後の内径変動などを極力抑制することなどが挙げられる。 Although the hollow fiber membrane of the present invention is an asymmetric structure membrane as described above, the thickness can be made thinner than before, and consideration is given to making the permeation resistance of the removed substance as small as possible. In addition, by taking into account the suppression of the formation of secondary layers and clogging of the pores by increasing the smoothness of the inner surface that can be said to be the entrance of the hollow fiber membrane when the removed substance moves from the blood to the dialysate side Yes. That is, in order to improve the smoothness of the inner surface, after the film-forming solution is discharged from the nozzle, the inner surface is quickly solidified (fixed) before being affected by disturbance, so that phase separation does not proceed excessively. Examples thereof include not applying an external force such as stretching the inner surface after being solidified and solidified, and suppressing fluctuations in the inner diameter after the hollow fiber membrane structure is fixed as much as possible.
内表面を素早く凝固させるためには、製膜原液に対して凝固性の高い内液を用いたり、凝固しやすい製膜原液組成や温度条件を採用するなどが挙げられる。本発明においては、セルロースアセテート系製膜原液に対して凝固性の高い水を主体とした内液を用いるのが好ましい。水のほか、一般的にセルロースアセテート系ポリマーの非溶剤として用いられるエチレングリコールやトリエチレングリコール、ポリエチレングリコール200または400、グリセリン、プロピレングリコールなどもそれぞれ単独または混合して用いることができる。水を主体とした内液を用いる場合は、水以外の成分として、前記非溶剤やセルローストリアセテート系ポリマーの溶剤であるN−メチルピロリドンやジメチルアセトアミド、ジメチルホルムアミド、ジメチルスルホキシドなどを5重量%を上限として添加することができる。 In order to rapidly solidify the inner surface, an internal solution having a high coagulation property with respect to the film-forming stock solution, or a film-forming stock solution composition and temperature conditions that easily coagulate can be used. In the present invention, it is preferable to use an internal liquid mainly composed of water having a high coagulation property with respect to the cellulose acetate film-forming stock solution. In addition to water, ethylene glycol, triethylene glycol, polyethylene glycol 200 or 400, glycerin, propylene glycol, etc., which are generally used as non-solvents for cellulose acetate polymers, can be used alone or in combination. When using an internal liquid mainly composed of water, the upper limit is 5% by weight as components other than water, such as N-methylpyrrolidone, dimethylacetamide, dimethylformamide, and dimethylsulfoxide, which are solvents for the non-solvent and cellulose triacetate polymers. Can be added as
また、先述したように製膜原液と内液を二重管状ノズルより吐出する際、製膜原液と内液との間に温度差を設ける技術を開発したことが、内表面の凝固性(凝固速度)を高めるうえで重要なポイントとなっている。製膜原液に対して内液の温度を低くすればするほど凝固性が高まる(凝固速度が速まる)が、製膜原液と内液との間に温度差を設けることは技術的な困難性が伴う。本発明者は、この点について鋭意検討した結果、吐出直前まで製膜原液と内液とを別々に温度コントロールできるようにノズルブロック内を熱媒(冷媒)が循環可能な構造に加工したものを用いることにより、この課題を解決した。1つのノズルブロックには、通常数十のノズルが組み込まれており、それらを均一に温度コントロールする配慮も必要であり、このような技術的困難性をクリアした。 In addition, as described above, the technology for providing a temperature difference between the film-forming stock solution and the internal solution when the film-forming stock solution and the internal solution are discharged from the double tubular nozzle has been developed. It is an important point in increasing the speed. The lower the temperature of the inner solution relative to the stock solution, the higher the coagulation (the solidification rate increases). However, it is technically difficult to provide a temperature difference between the stock solution and the internal solution. Accompany. As a result of diligent investigation on this point, the present inventor has processed a structure in which a heat medium (refrigerant) can be circulated in the nozzle block so that the temperature of the raw film forming solution and the internal solution can be controlled separately until immediately before discharge. By using it, this problem was solved. One nozzle block usually has several tens of nozzles incorporated therein, and it is necessary to consider the temperature control of these nozzles uniformly. This technical difficulty has been cleared.
本発明の中空糸膜を製造するためには、製膜原液の温度を70〜110℃に設定し、内液の温度を0〜40℃に設定するのが好ましい。また、製膜原液と内液との間に50℃以上100℃以下の温度差を設けるのが好ましい。あまり温度差の設定を大きくしても、実際には熱伝導を抑えきれず、また温度差が小さすぎると凝固を促進できないので、温度差は40℃以上90℃以下がより好ましく、50℃以上85℃以下がさらに好ましい。 In order to produce the hollow fiber membrane of the present invention, it is preferable to set the temperature of the membrane forming stock solution to 70 to 110 ° C and the temperature of the internal solution to 0 to 40 ° C. Moreover, it is preferable to provide a temperature difference of 50 ° C. or more and 100 ° C. or less between the film forming stock solution and the internal solution. Even if the temperature difference is set too large, heat conduction cannot actually be suppressed, and if the temperature difference is too small, solidification cannot be promoted. Therefore, the temperature difference is preferably 40 ° C. or more and 90 ° C. or less, more preferably 50 ° C. or more. 85 ° C. or lower is more preferable.
凝固中および凝固した内表面に延伸を掛けるなどの外力を与えないためには、二重管状ノズルのサイズは特に重要であり、製膜原液吐出内径(スリット内径)は形成される中空糸膜内径と同等の寸法にしておく必要がある。製膜原液吐出外径(スリット外径)も形成される中空糸膜外径と同等の寸法にすることが望ましいが、ノズルの加工限界もあり要求をみたすことは難しい。加工精度の許す限り最小の径のノズルを使用することが望ましい。本発明の中空糸膜は先述したように、内径が140〜260μm程度、膜厚が10〜30μm程度であるが、この場合用いるノズルはスリット外径が220〜330μm、スリット内径が150〜270μm程度とするのが好ましい。このようなノズルを採用することによって、吐出された製膜原液と内液との界面摩擦を低減することが可能となり、また製膜原液の吐出線速度と引取り速度をほぼ同一にできるため中空糸膜内面の荒れを防ぐことが可能となる。本発明において、引取り速度は凝固浴の出口ローラー速度を指し、吐出線速度と引取り速度の比(吐出線速度/引取り速度=ノズルドラフト比)は0.9〜1.3であることが好ましい。より好ましくは1.0〜1.2である。本発明においては、従来にない小口径のノズルを使用できるようになったことが更なる性能向上に繋がっている。
ここで、製膜原液を吐出するときの吐出線速度は、製膜原液吐出量をノズルスリット外径(a)とノズルスリット内径(b)を用いて得られるスリット断面積で除して求める。
製膜原液の吐出線速度[m/min]=製膜原液吐出量/[π{(a/2)^2−(b/2)^2}]
The size of the double tubular nozzle is particularly important in order not to apply an external force such as stretching on the solidified inner surface and the solidified inner surface. The inner diameter of the membrane-forming solution discharge (slit inner diameter) is the inner diameter of the hollow fiber membrane to be formed. It is necessary to make it the same size as. Although it is desirable to make the outer diameter of the membrane-forming stock solution discharge outer diameter (slit outer diameter) equal to the outer diameter of the hollow fiber membrane to be formed, it is difficult to meet the demand due to the processing limit of the nozzle. It is desirable to use a nozzle with the smallest diameter that the processing accuracy allows. As described above, the hollow fiber membrane of the present invention has an inner diameter of about 140 to 260 μm and a film thickness of about 10 to 30 μm. The nozzle used in this case has a slit outer diameter of 220 to 330 μm and a slit inner diameter of about 150 to 270 μm. Is preferable. By adopting such a nozzle, it becomes possible to reduce the interfacial friction between the discharged film-forming stock solution and the internal solution, and the discharge linear speed and take-up speed of the film-forming stock solution can be made substantially the same, so that it is hollow. It becomes possible to prevent roughening of the inner surface of the yarn film. In the present invention, the take-off speed refers to the outlet roller speed of the coagulation bath, and the ratio of the discharge linear speed to the take-off speed (discharge linear speed / take-off speed = nozzle draft ratio) is 0.9 to 1.3. Is preferred. More preferably, it is 1.0-1.2. In the present invention, the ability to use an unprecedented small-diameter nozzle leads to further performance improvement.
Here, the discharge linear velocity at the time of discharging the film forming stock solution is obtained by dividing the film forming stock solution discharge amount by the slit cross-sectional area obtained using the nozzle slit outer diameter (a) and the nozzle slit inner diameter (b).
Discharge linear velocity of film forming stock solution [m / min] = film forming stock solution discharge amount / [π {(a / 2) ^ 2− (b / 2) ^ 2}]
また、中空糸膜を凝固した後、水洗以降の工程において、中空糸膜を極力延伸しないことが好ましい。本発明者は、延伸をかけずに中空糸膜を洗浄することに着眼し、中空糸膜の進行方向と同一方向に洗浄水を流すことにより中空糸膜に極力延伸をかけずに洗浄を行うという発想にたどりついた。中空糸膜の洗浄においては従来、表面更新による洗浄効率を向上させるため洗浄液は中空糸膜の進行方向と逆方向に流されているが、このため水洗槽を走行する中空糸膜にかかる洗浄液の抵抗が大きくなり、結果として中空糸膜の伸び分を吸収するために延伸をかける必要があった。しかし、中空糸膜と洗浄液を同一方向に流すことにより、中空糸膜の伸びを最小限に抑えることができ、水洗工程で中空糸膜の伸び量を吸収する必要がなくなり、水洗工程で実質的に無延伸とすることが可能となった。なお、実質的に無延伸であるとは水洗工程入口のローラー速度と出口のローラー速度がほぼ同一であることを意味する。 In addition, after the hollow fiber membrane is solidified, it is preferable that the hollow fiber membrane is not stretched as much as possible in the steps after washing with water. The present inventor pays attention to washing the hollow fiber membrane without stretching and performs washing without stretching the hollow fiber membrane as much as possible by flowing washing water in the same direction as the traveling direction of the hollow fiber membrane. I arrived at the idea. In the cleaning of the hollow fiber membrane, conventionally, the cleaning liquid is flowed in the direction opposite to the traveling direction of the hollow fiber membrane in order to improve the cleaning efficiency by surface renewal. The resistance increased, and as a result, it was necessary to apply stretching to absorb the elongation of the hollow fiber membrane. However, by flowing the hollow fiber membrane and the cleaning liquid in the same direction, the elongation of the hollow fiber membrane can be minimized, and it is not necessary to absorb the amount of elongation of the hollow fiber membrane in the water washing step, and the water washing step is substantially effective. It became possible to make it unstretched. In addition, being substantially unstretched means that the roller speed at the entrance of the washing step and the roller speed at the exit are substantially the same.
また、中空糸膜構造が固定した後の内径変動などを極力抑制することについては、特に乾燥工程における中空糸膜の収縮を抑えることが重要である。従来、内液に流動パラフィンを用いる均質構造膜の製造においては、乾燥時の加熱による流動パラフィンの体膨張により比較的効果的に径方向の収縮を抑制することができる。しかし、中空糸膜の細孔を容易に通過する内液を用いる場合には、膜自体に収縮に耐える強度を持たせる以外にない。本発明の中空糸膜は、先述したように非対称構造としながらも膜厚を非常に薄くしており、そのため膜断面中間部および外表面近傍にも比較的密な層を設けることにより強度を付与している。本発明の中空糸膜は、単糸あたりの破断強度が30〜40g、破断伸度が19〜30%、降伏強度が18〜30g、降伏伸度が2.3〜3.0%を達成している。 Moreover, it is important to suppress the shrinkage of the hollow fiber membrane particularly in the drying process for suppressing the inner diameter fluctuation after the hollow fiber membrane structure is fixed as much as possible. Conventionally, in the production of a homogeneous structure film using liquid paraffin as an internal liquid, radial shrinkage can be suppressed relatively effectively by the body expansion of liquid paraffin by heating during drying. However, in the case of using an internal liquid that easily passes through the pores of the hollow fiber membrane, there is no other way than to give the membrane itself the strength to withstand shrinkage. As described above, the hollow fiber membrane of the present invention has a very thin film thickness while having an asymmetric structure. Therefore, a relatively dense layer is provided also in the middle of the membrane cross section and in the vicinity of the outer surface to provide strength. doing. The hollow fiber membrane of the present invention achieves a breaking strength per single yarn of 30 to 40 g, a breaking elongation of 19 to 30%, a yield strength of 18 to 30 g, and a yield elongation of 2.3 to 3.0%. ing.
本発明において、中空糸膜の強伸度を前記範囲にするためには、紡糸原液中のポリマー濃度やノズル温度を適正にすることに加え、凝固条件を適正化することも有効である。凝固浴の組成としては、溶剤、非溶剤、水からなる混合液を用いるのが好ましい。溶剤、非溶剤としては、製膜原液の調製に用いたのと同じ溶剤を用いるのが好ましい。なお、凝固浴への非溶剤の添加は特に必要ないが、凝固浴組成の変化を抑制する意味から紡糸原液中の溶剤/非溶剤比に合わせるのが好ましい。 In the present invention, in order to make the high elongation of the hollow fiber membrane within the above range, it is effective to optimize the coagulation conditions in addition to the polymer concentration and the nozzle temperature in the spinning dope. As the composition of the coagulation bath, it is preferable to use a mixed solution comprising a solvent, a non-solvent, and water. As the solvent and non-solvent, it is preferable to use the same solvent as that used for the preparation of the stock solution. Although addition of a non-solvent to the coagulation bath is not particularly required, it is preferable to match the solvent / non-solvent ratio in the spinning dope from the viewpoint of suppressing changes in the coagulation bath composition.
本発明において、中空糸膜の外表面の開孔率は7%以上30%以下が好ましい。外表面開孔率が大きすぎると、総じて中間(支持)層の空隙率が高くなるため、中空糸膜に必要な強度を確保できないとか、膜孔保持剤の保持性が低下する可能性がある。一方、中空糸膜の外表面開孔率が小さすぎると、細孔の非対称性が失われ均質構造に近づいていくことになるので、物質の透過性やろ過安定性が低下することがある。また、中空糸膜の透過拡散特性が低下するためオンラインでの洗浄効率が低下することがある。したがって、中空糸膜の外表面開孔率は8%以上25%以下がより好ましく、20%以下がさらに好ましく、18%以下が特に好ましい。 In the present invention, the porosity of the outer surface of the hollow fiber membrane is preferably 7% or more and 30% or less. If the outer surface open area ratio is too large, the porosity of the intermediate (support) layer generally increases, so that the strength required for the hollow fiber membrane cannot be secured, or the retainability of the membrane pore retainer may be reduced. . On the other hand, if the outer surface open area ratio of the hollow fiber membrane is too small, the asymmetry of the pores is lost and it approaches a homogeneous structure, so that the permeability and filtration stability of the substance may be lowered. Moreover, since the permeation | diffusion characteristic of a hollow fiber membrane falls, online washing | cleaning efficiency may fall. Therefore, the outer surface open area ratio of the hollow fiber membrane is more preferably 8% or more and 25% or less, further preferably 20% or less, and particularly preferably 18% or less.
外表面開孔率を上記範囲にするためには、製膜原液中のポリマー濃度やノズル温度などが影響するが、加えてノズルから吐出された紡糸原液が凝固浴に浸漬されるまでの間の空中走行部の長さを10mm以上150mm以下とするのが好ましい。また、空中走行部を外気と遮断し、内部を0℃以上50℃以下に設定することが好ましい。空中走行部の長さと温度を前記範囲とすることにより、ノズルから吐出された製膜原液の外表面側のポリマー核の成長を促進することができる。一方、製膜原液の内表面側では外表面側からの脱溶剤の影響を受けるより前に、芯液によるポリマーの凝固を完了させ緻密層を形成させることが可能となる。紡糸製膜の安定性を高めるためには空中走行部の長さは10mm以上100mm以下がより好ましく、紡糸口金からの紡糸原液の吐出斑の影響を相殺するには15mm以上80mm以下がさらに好ましい。 In order to make the outer surface area porosity within the above range, the polymer concentration in the film forming stock solution and the nozzle temperature are affected, but in addition, the spinning stock solution discharged from the nozzle is immersed in the coagulation bath. It is preferable that the length of the aerial traveling unit is 10 mm or more and 150 mm or less. Moreover, it is preferable to block the aerial traveling part from the outside air and set the interior to 0 ° C. or more and 50 ° C. or less. By setting the length and temperature of the aerial traveling portion within the above ranges, it is possible to promote the growth of polymer nuclei on the outer surface side of the film-forming stock solution discharged from the nozzle. On the other hand, on the inner surface side of the film-forming stock solution, it is possible to complete the solidification of the polymer by the core solution and form a dense layer before being affected by the solvent removal from the outer surface side. In order to improve the stability of the spinning film formation, the length of the aerial traveling section is more preferably 10 mm or more and 100 mm or less, and more preferably 15 mm or more and 80 mm or less in order to offset the influence of the discharge spots of the spinning stock solution from the spinneret.
本発明において、適正な中空糸膜外表面を得るためには凝固条件を適正化することも有効な手段の1つである。外表面の開孔率を高めるためには凝固浴中の溶剤濃度を高め、温度を高めることが有効である。溶剤濃度や温度を高めることにより空中走行部で生成したポリマー核をより成長させることができ、開孔率、開孔径を拡大することが可能となる。開孔率を前記範囲とするためには、凝固浴中の溶剤濃度を40重量%以上60重量%以下、温度を30℃以上60℃以下とするのが好ましい。凝固浴からの中空糸膜の曳きだし性を確保するには、溶剤濃度は45重量%以上60重量%以下、温度は30℃以上50℃以下がより好ましく、溶剤濃度は45重量%以上55重量%以下、温度は35℃以上45℃以下がさらに好ましい。 In the present invention, in order to obtain an appropriate outer surface of the hollow fiber membrane, it is one effective means to optimize the coagulation conditions. In order to increase the porosity of the outer surface, it is effective to increase the solvent concentration in the coagulation bath and increase the temperature. By increasing the solvent concentration and temperature, polymer nuclei generated in the aerial traveling part can be further grown, and the hole area ratio and the hole diameter can be increased. In order to set the open area ratio within the above range, the solvent concentration in the coagulation bath is preferably 40% by weight to 60% by weight and the temperature is preferably 30 ° C. or more and 60 ° C. or less. In order to ensure that the hollow fiber membrane is pierced from the coagulation bath, the solvent concentration is preferably 45% by weight or more and 60% by weight or less, the temperature is preferably 30 ° C. or more and 50 ° C. or less, and the solvent concentration is 45% by weight or more and 55% by weight. %, And the temperature is more preferably 35 ° C. or higher and 45 ° C. or lower.
凝固浴から曳き出した中空糸膜は、引き続き水洗浴にて過剰の溶媒、非溶媒を除去するために洗浄を行う。短時間に洗浄を行うためには、水洗浴の温度を出来るだけ高くする方がよい。しかし、温度が高すぎると、膜構成材料の劣化や膜形状、膜構造に欠陥が生じる可能性もあるので、50〜90℃程度で洗浄を行うのが好ましく、60〜90℃がより好ましく、70〜85℃がさらに好ましい。 The hollow fiber membrane squeezed out from the coagulation bath is subsequently washed in a water washing bath to remove excess solvent and non-solvent. In order to perform cleaning in a short time, it is better to raise the temperature of the washing bath as much as possible. However, if the temperature is too high, the film constituent material may be deteriorated and the film shape and the film structure may be defective. Therefore, it is preferable to perform the cleaning at about 50 to 90 ° C, more preferably 60 to 90 ° C. 70-85 degreeC is further more preferable.
水洗工程を経た中空糸膜は続いて、細孔内部への親水化剤の充填工程へ移行させる。本発明においては、グリセリン水溶液への中空糸膜の浸漬、液切りを繰り返し行うことで、細孔内部への親水化剤であるグリセリン水溶液を充填する。ここで、グリセリンの濃度は70〜95重量%とするのが好ましい。グリセリン濃度が低すぎると、後段の中空糸膜乾燥工程における水分蒸発に伴う細孔径の縮小や中空糸膜形状の変形(潰れ、偏平化)が起こる可能性がある。また、グリセリン濃度が高すぎると、流動性が低下するために充填や置換が不十分になることがある。したがって、グリセリン濃度は75〜95重量%がより好ましく、80〜90重量%がさらに好ましい。グリセリン水溶液の温度は、グリセリン濃度にもよるが、前記範囲であれば、80〜95℃程度が好ましい。このような温度範囲であれば、グリセリン水溶液の流動性が確保され、充填性や置換性の面で好ましい。本発明において、グリセリン水溶液への浸漬、液切りの各時間や頻度は、中空糸膜の内径や膜厚、膜構造にも関係するので一概には言えないが、本発明の中空糸膜の場合、浸漬、液切りを各3〜10秒程度、浸漬、液切りを1工程として3〜10回程度行えば足りるといえる。細孔内部にグリセリン水溶液が充填された中空糸膜は、乾燥工程を経てボビンにチーズ状に巻き取る。 The hollow fiber membrane that has undergone the water washing step is then transferred to the step of filling the pores with the hydrophilizing agent. In the present invention, the hollow fiber membrane is immersed in the glycerin aqueous solution and drained repeatedly to fill the pores with the glycerin aqueous solution as a hydrophilizing agent. Here, the concentration of glycerin is preferably 70 to 95% by weight. If the glycerin concentration is too low, the pore diameter may be reduced and the hollow fiber membrane shape may be deformed (crushed or flattened) due to moisture evaporation in the subsequent hollow fiber membrane drying step. On the other hand, if the glycerin concentration is too high, the fluidity is lowered and filling and replacement may be insufficient. Therefore, the glycerin concentration is more preferably 75 to 95% by weight, and further preferably 80 to 90% by weight. The temperature of the glycerin aqueous solution depends on the glycerin concentration, but is preferably about 80 to 95 ° C. within the above range. If it is such a temperature range, the fluidity | liquidity of glycerin aqueous solution will be ensured and it is preferable at the surface of a filling property or substitution property. In the present invention, the time and frequency of immersing in the glycerin aqueous solution and draining are not unambiguous because they relate to the inner diameter, film thickness, and membrane structure of the hollow fiber membrane, but in the case of the hollow fiber membrane of the present invention It can be said that it is sufficient to perform immersion and liquid draining for about 3 to 10 seconds each, and performing immersion and liquid draining for about 3 to 10 times as one step. A hollow fiber membrane filled with an aqueous glycerin solution inside the pores is wound around a bobbin in a cheese shape through a drying process.
本発明の中空糸膜を用いて内径基準による膜面積が1.5m2のモジュールを作製すると、血液流路側にヒトβ2MG(分子量18,000)を0.05〜0.1mg/lの濃度になるように添加した総タンパク質濃度が6.5±0.5g/dl、37℃に保温したACD添加牛血漿を流量200ml/min、透析液側に透析液を500ml/min、ろ過流量15ml/minで流した際に、透析開始後60分時点および240分時点のβ2MGのクリアランス(それぞれCLβ15[60]、CLβ15[240]とする)が65ml/min以上を達成することができ、ダイアライザー機能分類のV型性能を発現することも可能である。なお、CLβ15[240]/CLβ15[60]≧0.93を満たすことが好ましい。 When a module having a membrane area of 1.5 m 2 based on the inner diameter standard is produced using the hollow fiber membrane of the present invention, human β2MG (molecular weight 18,000) is added to the blood flow channel side at a concentration of 0.05 to 0.1 mg / l. The total protein concentration so added was 6.5 ± 0.5 g / dl, the ACD-added bovine plasma kept at 37 ° C. was flowed at 200 ml / min, the dialysate on the dialysate side was 500 ml / min, and the filtration flow was 15 ml / min. , The clearance of β2MG at 60 minutes and 240 minutes after the start of dialysis (respectively CLβ15 [60] and CLβ15 [240]) can reach 65 ml / min or more. It is also possible to develop V-type performance. It is preferable that CLβ15 [240] / CLβ15 [60] ≧ 0.93 is satisfied.
また、本発明の中空糸膜は、細孔の目詰まりや2次層の生成を抑える配慮を施しているので、前記β2MGに代表される低分子タンパクの透過性を高めることができるだけでなく、ろ過流量を高めた際の透過性能の安定性や経時安定性をも高めることが可能となった。すなわち、前記試験において、ろ過流量15ml/minのときのβ2MGのクリアランス(CLβ15[60])と、ろ過流量45ml/minのときのβ2MGのクリアランス(CLβ45[60])との比(CLβ45[60]/CLβ15[60])が1.05以上を達成している。 In addition, the hollow fiber membrane of the present invention is not only capable of enhancing the permeability of low molecular weight proteins typified by β2MG, because it has taken into consideration the suppression of pore clogging and the formation of secondary layers. It became possible to improve the stability of permeation performance and the stability over time when the filtration flow rate was increased. That is, in the test, the ratio (CLβ45 [60]) of β2MG clearance (CLβ15 [60]) when the filtration flow rate is 15 ml / min and β2MG clearance (CLβ45 [60]) when the filtration flow rate is 45 ml / min. / CLβ15 [60]) is 1.05 or more.
さらに、本発明の中空糸膜は、ろ過流量15ml/minの条件で試験したとき3L除水換算(一般的な血液透析療法に相当)のタンパクリーク量が2g以下という非常に低い漏出量を達成している。また、ろ過流量45ml/minの条件で試験したとき、除水量10L換算(血液ろ過透析療法に相当)のタンパクリーク量が5g以下を達成することも可能である。 Furthermore, the hollow fiber membrane of the present invention achieves a very low amount of protein leakage of 3 g or less (equivalent to general hemodialysis therapy) of protein leakage of 2 g or less when tested at a filtration flow rate of 15 ml / min. doing. Further, when tested under the condition of a filtration flow rate of 45 ml / min, it is also possible to achieve a protein leak amount of 5 g or less in terms of water removal amount of 10 L (corresponding to blood filtration dialysis therapy).
以下、本発明について実施例を挙げて更に具体的に説明するが、本発明は、これらの実施例によって何ら限定されるものではない。 EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated more concretely, this invention is not limited at all by these Examples.
(中空糸膜の内径、外径、膜厚の測定)
中空糸膜断面のサンプルは以下のようにして得ることができる。測定には芯液を洗浄、除去した後、中空糸膜を乾燥させた形態で観察することが好ましい。乾燥方法は問わないが、乾燥により著しく形態が変化する場合には芯液を洗浄、除去したのち、純水で置換した後、湿潤状態で形態を観察することが好ましい。中空糸膜の内径、外径および膜厚は、中空糸膜をスライドグラスの中央に開けられたφ3mmの孔に中空糸膜が抜け落ちない程度に適当本数通し、スライドグラスの上下面でカミソリによりカットし、中空糸膜断面サンプルを得た後、投影機Nikon−V−12Aを用いて中空糸膜断面の短径、長径を測定することにより得られる。中空糸膜断面1個につき2方向の短径、長径を測定し、それぞれの算術平均値を中空糸膜断面1個の内径および外径とし、膜厚は(外径−内径)/2で算出する。5断面について同様に測定を行い、平均値を内径、膜厚とする。
(Measurement of hollow fiber membrane inner diameter, outer diameter, film thickness)
A sample of the cross section of the hollow fiber membrane can be obtained as follows. For the measurement, it is preferable to observe in a form in which the hollow fiber membrane is dried after washing and removing the core liquid. There is no limitation on the drying method, but when the form changes remarkably by drying, it is preferable to observe the form in a wet state after washing and removing the core liquid and replacing with pure water. The hollow fiber membrane has an inner diameter, an outer diameter, and a film thickness. The hollow fiber membrane is cut through a razor on the top and bottom surfaces of the slide glass so that the hollow fiber membrane does not fall out into a hole of φ3 mm in the center of the slide glass. And after obtaining the hollow fiber membrane cross-section sample, it is obtained by measuring the minor axis and major axis of the hollow fiber membrane cross section using a projector Nikon-V-12A. Measure the short axis and long axis in two directions for each cross section of the hollow fiber membrane, and calculate the arithmetic average value of each of the cross section of the hollow fiber membrane as the inner diameter and outer diameter of one hollow fiber membrane. To do. The same measurement is performed for five cross sections, and the average value is defined as the inner diameter and film thickness.
(中空糸膜の開孔率の測定)
中空糸膜を10,000倍の走査型電子顕微鏡で観察し、写真(SEM写真)を撮影する。その画像より、縦762pixel×横620pixelの領域を切り出した後、画像解析ソフトを使用し、白/黒に画像を二値化し、中空糸膜表面および各断面の開孔率を求める。取り込んだ画像を孔部と閉塞部が識別されるように強調・フィルタ操作を実施する。その後、孔部をカウントし、孔内部に下層のポリマー鎖が見て取れる場合には、孔を結合して一孔とみなしてカウントする。測定範囲の面積(A)、および測定範囲内の孔の面積の累計(B)を求めて開孔率(%)=B/A×100を求める。これを10視野実施してその平均を求める。初期操作としてスケール設定を実施するものとし、また、カウント時には測定範囲境界上の孔は除外しないものとする。
断面の開孔率測定は中空糸断面を内側から外側に向けてほぼ均等の長さに5分割し(内表面から外表面に向かって、順に断面1、2、3、4、5とする)、それぞれの開孔率を測定する。
(Measurement of open area of hollow fiber membrane)
The hollow fiber membrane is observed with a scanning electron microscope of 10,000 times, and a photograph (SEM photograph) is taken. An area of 762 pixels in the vertical direction and 620 pixels in the horizontal direction is cut out from the image, and then the image is binarized into white / black using image analysis software to obtain the hollow fiber membrane surface and the open area ratio of each cross section. The emphasis / filtering operation is performed on the captured image so that the hole and the blockage are identified. Thereafter, the holes are counted, and when the lower polymer chain can be seen inside the holes, the holes are combined and counted as one hole. The area (A) of the measurement range and the total area (B) of the holes in the measurement range are obtained to obtain the hole area ratio (%) = B / A × 100. This is carried out for 10 visual fields and the average is obtained. Scale setting is performed as an initial operation, and holes on the measurement range boundary are not excluded during counting.
To measure the open area ratio of the cross section, the hollow fiber cross section is divided into five sections of substantially equal length from the inside to the outside (the sections 1, 2, 3, 4 and 5 are sequentially formed from the inner surface to the outer surface). Then, the respective aperture ratios are measured.
(平均面粗さ(Ra値)の測定)
評価する中空糸膜の内表面を露出させたものを試料とした。原子間力顕微鏡SPI3800(セイコーインスツルメンツ社製)によって形態観察した。この時の観察モードはDFMモード、スキャナーはFS−20A、カンチレバーはDF−3、観測視野は3μm四方である。Ra値は膜表面の凹凸を測定した際の基準点に対する全測定点の凹凸の算術平均を表す。
(Measurement of average surface roughness (Ra value))
A sample in which the inner surface of the hollow fiber membrane to be evaluated was exposed was used. The morphology was observed with an atomic force microscope SPI3800 (manufactured by Seiko Instruments Inc.). The observation mode at this time is the DFM mode, the scanner is FS-20A, the cantilever is DF-3, and the observation field is 3 μm square. Ra value represents the arithmetic average of the unevenness | corrugation of all the measurement points with respect to the reference point at the time of measuring the unevenness | corrugation of the film | membrane surface.
(透水率(UFR)の測定)
透析器の血液出口部回路(圧力測定点よりも出口側)を鉗子で挟んで封止する。37℃に保温した純水を加圧タンクに入れ、レギュレーターにより圧力を制御しながら、37℃恒温槽で保温した透析器へ純水を送り、透析液側から流出した濾液流量を測定する。膜間圧力差(TMP)は
TMP=(Pi+Po)/2
とする。ここでPiは透析器入り口側圧力、Poは透析器出口側圧力である。TMPを4点変化させ濾過流量を測定し、それらの関係の傾きから透水率(mL/hr/mmHg)を算出する。このときTMPと濾過流量の相関係数は0.999以上でなくてはならない。また、回路による圧力損失誤差を少なくするために、TMPは100mmHg以下の範囲で測定する。中空糸膜の透水率は膜面積と透析器の透水率から算出する。
UFR(H)=UFR(D)/A
ここでUFR(H)は中空糸膜の透水率(mL/m2/hr/mmHg)、UFR(D)は透析器の透水率(mL/hr/mmHg)、Aは透析器の膜面積(m2)である。
(Measurement of water permeability (UFR))
The blood outlet circuit of the dialyzer (the outlet side from the pressure measurement point) is sealed with forceps. Pure water kept at 37 ° C. is put into a pressurized tank, and while controlling the pressure with a regulator, pure water is sent to the dialyzer kept at 37 ° C. in a constant temperature bath, and the flow rate of the filtrate flowing out from the dialysate side is measured. The transmembrane pressure difference (TMP) is TMP = (Pi + Po) / 2
And Here, Pi is the dialyzer inlet side pressure, and Po is the dialyzer outlet side pressure. The TMP is changed at four points, the filtration flow rate is measured, and the water permeability (mL / hr / mmHg) is calculated from the slope of the relationship. At this time, the correlation coefficient between TMP and the filtration flow rate must be 0.999 or more. In order to reduce the pressure loss error due to the circuit, TMP is measured in the range of 100 mmHg or less. The water permeability of the hollow fiber membrane is calculated from the membrane area and the water permeability of the dialyzer.
UFR (H) = UFR (D) / A
Here, UFR (H) is the water permeability of the hollow fiber membrane (mL / m 2 / hr / mmHg), UFR (D) is the water permeability of the dialyzer (mL / hr / mmHg), and A is the membrane area of the dialyzer (mL m 2 ).
(β2MGのクリアランス測定)
非特許文献1に示された血液浄化器性能評価基準に準じ実施する。膜面積1.5m2(中空糸膜内径基準)の血液浄化器に、総タンパク質濃度6.5±0.5g/dlに調整し、37℃に保温したACD(acid−citrate−dextrose)添加牛血漿を血液側流量200ml/minで1時間循環する。次いでヒトβ2MG(遺伝子組み換え品、和光純薬製)を0.05〜0.1mg/lの濃度になるように添加した総タンパク質濃度6.5±0.5g/dlに調整し、37℃に保温したACD添加牛血漿を血液側流量200ml/minで血液側に流し、市販透析液を500ml/min、ろ過流量15ml/minまたは45ml/minで透析を実施する。このクリアランス評価はシングルパスで実施する。透析開始後、60分時点、240分時点の血液入口、出口、透析液出口より採取した試験液のβ2MG濃度を測定する。クリアランスは以下の式で計算する。
・ろ過流量15ml/min、60分時点および240分時点のクリアランス(CLβ15[60]、[240])
CLβ15(ml/min)=200×[(200×CBi)−(185×CBo)]/(200×CBi)
・ろ過流量45ml/min、60分時点および240分時点のクリアランス(CLβ45[60]、[240])
CLβ45(ml/min)=200×[(200×CBi)−(155×CBo)]/(200×CBi)
ここで、CBi;血液入口部濃度、CBo;血液出口部濃度。
(Measurement of β2MG clearance)
It carries out according to the blood purifier performance evaluation criteria shown in Non-Patent Document 1. ACD (acid-citrate-dextrose) -added cow adjusted to a total protein concentration of 6.5 ± 0.5 g / dl and kept at 37 ° C. in a blood purifier having a membrane area of 1.5 m 2 (inside of hollow fiber membrane inner diameter) Plasma is circulated for 1 hour at a blood flow rate of 200 ml / min. Next, human β2MG (genetical recombination product, manufactured by Wako Pure Chemical Industries, Ltd.) was added to a concentration of 0.05 to 0.1 mg / l, and the total protein concentration was adjusted to 6.5 ± 0.5 g / dl. The kept ACD-added bovine plasma is flowed to the blood side at a blood flow rate of 200 ml / min, and dialysis is performed at a commercial dialysate of 500 ml / min and a filtration flow rate of 15 ml / min or 45 ml / min. This clearance evaluation is performed with a single pass. After the start of dialysis, the β2MG concentration of the test solution collected from the blood inlet / outlet and the dialysate outlet at 60 minutes and 240 minutes is measured. The clearance is calculated using the following formula.
Filtration flow rate 15 ml / min, clearance at 60 minutes and 240 minutes (CLβ15 [60], [240])
CLβ15 (ml / min) = 200 × [(200 × CBi) − (185 × CBo)] / (200 × CBi)
Filtration flow rate 45 ml / min, clearance at 60 minutes and 240 minutes (CLβ45 [60], [240])
CLβ45 (ml / min) = 200 × [(200 × CBi) − (155 × CBo)] / (200 × CBi)
Here, CBi: blood inlet concentration, CBo: blood outlet concentration.
(タンパクリーク量の測定)
クエン酸を添加し、凝固を抑制した牛血液をヘマトクリット25〜30%、タンパク濃度6〜7g/dlに調製し、37℃で血液浄化器に200ml/minで送液し、ろ過流量15ml/minまたは45ml/minで血液をろ過する。このとき、ろ液は血液に戻し、循環系とする。15分毎にろ過流量を測定し、血液浄化器のろ液を採取する。ろ液に含有するタンパクの濃度を測定する。血漿中のタンパク濃度の測定は、体外診断用のキット(マイクロTP−テストワコー、和光純薬工業社製)を用いて行う。2時間までのデータをもとに、下の式から平均タンパクリーク量を求め、3L除水換算時のタンパクリーク量(TPL)を算出する。
積算ろ過量(ml)=t1(min)×Ct1(ml/min)+(t2−t1)(min)×Ct2(ml/min)+(t3−t2)(min)×Ct3(ml/min)・・・・(t120−tn)(min)×C120min(ml/min)
t:測定時間(min)、C:ろ過流量(ml/min)
ろ液のタンパク濃度=a×Ln(積算ろ過量)+b
各測定点におけるろ液のタンパク濃度とLn(積算ろ過量)からa、bを求める。
TPL(平均)=−a+b+a×Ln(積算ろ過量×2)
TPL(3L除水換算)(g)=TPL(平均)×30/1000
TPL(10L除水換算)(g)=TPL(平均)×100/1000
(Measurement of protein leak)
Bovine blood to which citric acid was added and coagulation was suppressed was adjusted to a hematocrit of 25 to 30% and a protein concentration of 6 to 7 g / dl, and sent to a blood purifier at 37 ml at a rate of 200 ml / min, and a filtration flow rate of 15 ml / min. Alternatively, the blood is filtered at 45 ml / min. At this time, the filtrate is returned to blood to be a circulatory system. Measure the filtration flow rate every 15 minutes and collect the filtrate from the blood purifier. Measure the protein concentration in the filtrate. Measurement of protein concentration in plasma is performed using an in vitro diagnostic kit (Micro TP-Test Wako, manufactured by Wako Pure Chemical Industries, Ltd.). Based on the data for up to 2 hours, the average protein leak amount is obtained from the following formula, and the protein leak amount (TPL) at the time of 3 L water removal conversion is calculated.
Integrated filtration amount (ml) = t 1 (min) × C t1 (ml / min) + (t 2 −t 1 ) (min) × C t2 (ml / min) + (t 3 −t 2 ) (min) × C t3 (ml / min)... (T 120 −t n ) (min) × C 120 min (ml / min)
t: Measurement time (min), C: Filtration flow rate (ml / min)
Protein concentration in the filtrate = a × Ln (integrated filtration amount) + b
A and b are determined from the protein concentration of the filtrate at each measurement point and Ln (integrated filtration amount).
TPL (average) = − a + b + a × Ln (integrated filtration amount × 2)
TPL (converted to 3L water removal) (g) = TPL (average) × 30/1000
TPL (converted to 10L water removal) (g) = TPL (average) × 100/1000
(破断強伸度、降伏強伸度の測定)
中空糸膜の強伸度は、テンシロン万能試験機(東洋ボールドウィン社製UTMII)を用い、乾燥した中空糸膜1本を約15cmの長さに切断してチャック間(距離約10cm)に弛みのないよう取り付け、20±5℃、60±10%RHの温湿度環境下、クロスヘッドスピード10cm/minで中空糸膜を引張り、測定を行った。得られたチャート紙から中空糸膜が切れた破断伸度と破断強力を読み取る。図1に示すように、S−Sカーブより補助線を設け、二つの補助線が交差した点を降伏点と定義し、その点における強力を降伏強力、伸度を降伏伸度とする。
(Measurement of breaking strength and yield strength)
The tensile strength of the hollow fiber membrane was determined by using a Tensilon universal testing machine (UTMII manufactured by Toyo Baldwin) to cut one dried hollow fiber membrane into a length of about 15 cm and loosening between the chucks (distance about 10 cm). The hollow fiber membrane was pulled at a crosshead speed of 10 cm / min in a temperature and humidity environment of 20 ± 5 ° C. and 60 ± 10% RH, and measurement was performed. The breaking elongation and breaking strength at which the hollow fiber membrane is cut are read from the obtained chart paper. As shown in FIG. 1, an auxiliary line is provided from the SS curve, a point where two auxiliary lines intersect is defined as a yield point, and the strength at that point is defined as yield strength and the elongation as yield elongation.
(モジュール作製歩留まり)
紡糸された中空糸膜、約10,000本を束状に巻き取り、巻き取った中空糸膜束を透明のモジュールケースに挿入し、次いで、ケースの端部をウレタンやエポキシなどの樹脂で、中空糸膜束とケースを液密に接着、その後、中空糸膜の中空部が開口するように接着部分を切断し、中空糸膜モジュールを作製する。出来上がった中空糸膜モジュールを、目視にて外観検査を行い、中空糸膜に折れ、切れ、ねじれ、つぶれの形状異常の有無にて、作製歩留まりを算出する。本発明において、モジュール作製歩留まりは96%以上が好ましい。
(Module production yield)
About 10,000 of the spun hollow fiber membranes are wound into a bundle, the wound hollow fiber membrane bundle is inserted into a transparent module case, and then the end of the case is made of a resin such as urethane or epoxy, The hollow fiber membrane bundle and the case are bonded in a liquid-tight manner, and then the bonded portion is cut so that the hollow portion of the hollow fiber membrane is opened, thereby producing a hollow fiber membrane module. The appearance of the completed hollow fiber membrane module is visually inspected, and the production yield is calculated based on whether or not the hollow fiber membrane is bent, cut, twisted, or crushed. In the present invention, the module production yield is preferably 96% or more.
(実施例1)
セルローストリアセテート(6%粘度=162mPa・s、ダイセル化学工業社製)17重量%、N−メチルピロリドン(NMP、三菱化学社製)58.1重量%、トリエチレングリコール(TEG、三井化学社製)24.9重量%を均一に溶解したものを製膜原液として、スリット外径270μm、スリット内径200μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はノズルブロック中に15℃の冷媒を流し冷却した。また、製膜原液はブロック中に92℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は20mmのエアギャップ部を通過させた後、NMP/TEG/水=49/21/30からなる45℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.15であった。なお、水洗工程は中空糸膜と洗浄水を向流に流す従来法に従った。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は1.0%であった。凝固浴出口から巻き上げまでの総延伸は6%であった。得られた中空糸膜の内径は200μm、膜厚は19μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタン樹脂で接着固定し、中空糸膜内径基準の膜面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
Example 1
Cellulose triacetate (6% viscosity = 162 mPa · s, manufactured by Daicel Chemical Industries) 17% by weight, N-methylpyrrolidone (NMP, manufactured by Mitsubishi Chemical) 58.1% by weight, triethylene glycol (TEG, manufactured by Mitsui Chemicals) A solution obtained by uniformly dissolving 24.9% by weight was discharged as a film-forming stock solution from the slit portion of a double-tube nozzle having a slit outer diameter of 270 μm and a slit inner diameter of 200 μm, and at the same time, water was discharged as the inner liquid. At that time, the internal liquid was cooled by flowing a 15 ° C. refrigerant through the nozzle block. The film-forming stock solution was heated by circulating a heating medium at 92 ° C. in the block.
The film-forming stock solution discharged from the nozzle is allowed to pass through a 20 mm air gap, and then guided into a 45 ° C. coagulation bath consisting of NMP / TEG / water = 49/21/30, solidified, washed with water, and treated with glycerin. After that, it was dried and wound up. The nozzle draft ratio was 1.15. In addition, the water washing process followed the conventional method in which a hollow fiber membrane and washing water are made to flow countercurrently. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 1.0%. The total stretching from the coagulation bath outlet to winding was 6%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 19 μm. The obtained hollow fiber membrane was bundled and inserted into a case, and both ends were bonded and fixed with polyurethane resin, and a module having a hollow fiber membrane inner diameter standard membrane area of 1.5 m 2 was produced and subjected to various evaluations. . The evaluation results are summarized in Table 2.
(実施例2)
セルローストリアセテート(6%粘度=154mPa・s、ダイセル化学工業社製)17重量%をN−メチルピロリドン(三菱化学社製)58.1重量%とトリエチレングリコール(三井化学社製)24.9重量%の混合物を均一に溶解したものを製膜原液として、スリット外径270μm、スリット内径200μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はノズルブロック中に35℃の冷媒を流し冷却した。また、製膜原液はブロック中に92℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は20mmのエアギャップ部を通過させた後、NMP/TEG/水=49/21/30からなる40℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.15であった。なお水洗槽は、傾きを2.5度とし、洗浄水が緩やかに下っていくように調整し、洗浄水を中空糸膜と同じ並流に流した。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は0%であった。凝固浴出口から巻き上げまでの総延伸は4%であった。得られた中空糸膜の内径は200μm、膜厚は20μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタンで接着固定し、中空糸膜内径基準の有効面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
(Example 2)
17% by weight of cellulose triacetate (6% viscosity = 154 mPa · s, manufactured by Daicel Chemical Industries), 58.1% by weight of N-methylpyrrolidone (manufactured by Mitsubishi Chemical) and 24.9% by weight of triethylene glycol (manufactured by Mitsui Chemicals) % As a film-forming stock solution was discharged from a slit portion of a double-tube nozzle having a slit outer diameter of 270 μm and a slit inner diameter of 200 μm, and water was simultaneously discharged as an inner liquid. At that time, the internal liquid was cooled by flowing a 35 ° C. refrigerant through the nozzle block. The film-forming stock solution was heated by circulating a heating medium at 92 ° C. in the block.
The film-forming stock solution discharged from the nozzle is allowed to pass through a 20 mm air gap, and is then solidified by being guided into a 40 ° C. coagulation bath consisting of NMP / TEG / water = 49/21/30, followed by washing with water and glycerin adhesion treatment. After that, it was dried and wound up. The nozzle draft ratio was 1.15. The washing tank was adjusted to have an inclination of 2.5 degrees so that the washing water gradually descended, and the washing water was allowed to flow in the same co-current as the hollow fiber membrane. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 0%. The total stretching from the coagulation bath outlet to winding was 4%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 20 μm. The obtained hollow fiber membranes were bundled and inserted into a case, and both ends were bonded and fixed with polyurethane, and modules having an effective area of 1.5 m 2 based on the hollow fiber membrane inner diameter standard were prepared for various evaluations. The evaluation results are summarized in Table 2.
(実施例3)
セルローストリアセテート(6%粘度=154mPa・s、ダイセル化学工業社製)18重量%をN−メチルピロリドン(三菱化学社製)57.4重量%とトリエチレングリコール(三井化学社製)24.6重量%の混合物を均一に溶解したものを製膜原液として、スリット外径270μm、スリット内径200μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はノズルブロック中に15℃の冷媒を流し冷却した。また、製膜原液はブロック中に103℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は45mmのエアギャップ部を通過させた後、NMP/TEG/水=49/21/30からなる45℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.15であった。なお水洗槽は、傾きを2.5度とし、洗浄水が緩やかに下っていくように調整し、洗浄水を中空糸膜と同じ並流に流した。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は0%であった。凝固浴出口から巻き上げまでの総延伸は4%であった。得られた中空糸膜の内径は200μm、膜厚は19μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタンで接着固定し、中空糸膜内径基準の有効面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
(Example 3)
Cellulose triacetate (6% viscosity = 154 mPa · s, manufactured by Daicel Chemical Industries) 18% by weight, N-methylpyrrolidone (Mitsubishi Chemical Co., Ltd.) 57.4% by weight and triethylene glycol (Mitsui Chemicals) 24.6% by weight % As a film-forming stock solution was discharged from a slit portion of a double-tube nozzle having a slit outer diameter of 270 μm and a slit inner diameter of 200 μm, and water was simultaneously discharged as an inner liquid. At that time, the internal liquid was cooled by flowing a 15 ° C. refrigerant through the nozzle block. The film-forming stock solution was heated by circulating a heating medium at 103 ° C. in the block.
The film-forming stock solution discharged from the nozzle passes through a 45 mm air gap, and is then solidified by being guided into a 45 ° C. coagulation bath consisting of NMP / TEG / water = 49/21/30, followed by washing with water and glycerin adhesion treatment. After that, it was dried and wound up. The nozzle draft ratio was 1.15. The washing tank was adjusted to have an inclination of 2.5 degrees so that the washing water gradually descended, and the washing water was allowed to flow in the same co-current as the hollow fiber membrane. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 0%. The total stretching from the coagulation bath outlet to winding was 4%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 19 μm. The obtained hollow fiber membranes were bundled and inserted into a case, and both ends were bonded and fixed with polyurethane, and modules having an effective area of 1.5 m 2 based on the hollow fiber membrane inner diameter standard were prepared for various evaluations. The evaluation results are summarized in Table 2.
(実施例4)
セルローストリアセテート(6%粘度=154mPa・s、ダイセル化学工業社製)16.5重量%をN−メチルピロリドン(三菱化学社製)54.3重量%とトリエチレングリコール(三井化学社製)29.2重量%の混合物を均一に溶解したものを製膜原液として、スリット外径270μm、スリット内径200μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はノズルブロック中に30℃の冷媒を流し冷却した。また、製膜原液はブロック中に85℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は15mmのエアギャップ部を通過させた後、NMP/TEG/水=42/23/35からなる35℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.1であった。なお、水洗工程は中空糸膜と洗浄水を向流に流す従来法に従った。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は1.0%であった。凝固浴出口から巻き上げまでの総延伸は6%であった。得られた中空糸膜の内径は200μm、膜厚は21μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタンで接着固定し、中空糸膜内径基準の有効面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
Example 4
Cellulose triacetate (6% viscosity = 154 mPa · s, manufactured by Daicel Chemical Industries, Ltd.) 16.5% by weight, N-methylpyrrolidone (Mitsubishi Chemical Co., Ltd.) 54.3% by weight, and triethylene glycol (Mitsui Chemicals, Inc.) 29. A solution obtained by uniformly dissolving 2% by weight of the mixture was discharged as a film-forming stock solution from the slit portion of a double tube nozzle having a slit outer diameter of 270 μm and a slit inner diameter of 200 μm, and at the same time, water was discharged as the inner liquid. At that time, the internal liquid was cooled by flowing a 30 ° C. refrigerant through the nozzle block. The film forming stock solution was heated by circulating a heat medium at 85 ° C. in the block.
The film-forming stock solution discharged from the nozzle passes through a 15 mm air gap, and is then solidified by guiding it into a 35 ° C. coagulation bath consisting of NMP / TEG / water = 42/23/35, followed by washing with water and glycerin adhesion treatment. After that, it was dried and wound up. The nozzle draft ratio was 1.1. In addition, the water washing process followed the conventional method in which a hollow fiber membrane and washing water are made to flow countercurrently. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 1.0%. The total stretching from the coagulation bath outlet to winding was 6%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 21 μm. The obtained hollow fiber membranes were bundled and inserted into a case, and both ends were bonded and fixed with polyurethane, and modules having an effective area of 1.5 m 2 based on the hollow fiber membrane inner diameter standard were prepared for various evaluations. The evaluation results are summarized in Table 2.
(実施例5)
セルローストリアセテート(6%粘度=154mPa・s、ダイセル化学工業社製)17.5重量%をN−メチルピロリドン(三菱化学社製)57.8重量%とトリエチレングリコール(三井化学社製)24.7重量%の混合物を均一に溶解したものを製膜原液として、スリット外径270μm、スリット内径200μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はノズルブロック中に15℃の冷媒を流し冷却した。また、製膜原液はブロック中に97℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は45mmのエアギャップ部を通過させた後、NMP/TEG/水=49/21/30からなる45℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.15であった。なお水洗槽は、傾きを2.5度とし、洗浄水が緩やかに下っていくように調整し、洗浄水を中空糸膜と同じ並流に流した。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は0%であった。凝固浴出口から巻き上げまでの総延伸は4%であった。得られた中空糸膜の内径は200μm、膜厚は19μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタンで接着固定し、中空糸膜内径基準の有効面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
(Example 5)
Cellulose triacetate (6% viscosity = 154 mPa · s, manufactured by Daicel Chemical Industries) 17.5% by weight, N-methylpyrrolidone (Mitsubishi Chemical) 57.8% by weight and triethylene glycol (Mitsui Chemicals) 24. A solution in which 7% by weight of the mixture was uniformly dissolved was discharged from a slit portion of a double tube nozzle having a slit outer diameter of 270 μm and a slit inner diameter of 200 μm as a film forming stock solution, and at the same time, water was discharged as an inner liquid. At that time, the internal liquid was cooled by flowing a 15 ° C. refrigerant through the nozzle block. The film forming stock solution was heated by circulating a 97 ° C. heating medium in the block.
The film-forming stock solution discharged from the nozzle passes through a 45 mm air gap, and is then solidified by being guided into a 45 ° C. coagulation bath consisting of NMP / TEG / water = 49/21/30, followed by washing with water and glycerin adhesion treatment. After that, it was dried and wound up. The nozzle draft ratio was 1.15. The washing tank was adjusted to have an inclination of 2.5 degrees so that the washing water gradually descended, and the washing water was allowed to flow in the same co-current as the hollow fiber membrane. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 0%. The total stretching from the coagulation bath outlet to winding was 4%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 19 μm. The obtained hollow fiber membranes were bundled and inserted into a case, and both ends were bonded and fixed with polyurethane, and modules having an effective area of 1.5 m 2 based on the hollow fiber membrane inner diameter standard were prepared for various evaluations. The evaluation results are summarized in Table 2.
(実施例6)
セルローストリアセテート(6%粘度=172mPa・s、ダイセル化学工業社製)17重量%をN−メチルピロリドン(三菱化学社製)58.1重量%とトリエチレングリコール(三井化学社製)24.9重量%の混合物を均一に溶解したものを製膜原液として、スリット外径250μm、スリット内径185μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はノズルブロック中に15℃の冷媒を流し冷却した。また、製膜原液はブロック中に92℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は20mmのエアギャップ部を通過させた後、NMP/TEG/水=49/21/30からなる45℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.07であった。なお、水洗工程は中空糸膜と洗浄水を向流に流す従来法に従った。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は1.0%であった。凝固浴出口から巻き上げまでの総延伸は6%であった。得られた中空糸膜の内径は185μm、膜厚は16μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタンで接着固定し、中空糸膜内径基準の有効面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
(Example 6)
17% by weight of cellulose triacetate (6% viscosity = 172 mPa · s, manufactured by Daicel Chemical Industries), 58.1% by weight of N-methylpyrrolidone (manufactured by Mitsubishi Chemical) and 24.9% by weight of triethylene glycol (manufactured by Mitsui Chemicals) % As a film-forming stock solution was discharged from the slit portion of a double-tube nozzle having a slit outer diameter of 250 μm and a slit inner diameter of 185 μm, and water was simultaneously discharged as the inner liquid. At that time, the internal liquid was cooled by flowing a 15 ° C. refrigerant through the nozzle block. The film-forming stock solution was heated by circulating a heating medium at 92 ° C. in the block.
The film-forming stock solution discharged from the nozzle is allowed to pass through a 20 mm air gap, and then guided into a 45 ° C. coagulation bath consisting of NMP / TEG / water = 49/21/30, solidified, washed with water, and treated with glycerin. After that, it was dried and wound up. The nozzle draft ratio was 1.07. In addition, the water washing process followed the conventional method in which a hollow fiber membrane and washing water are made to flow countercurrently. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 1.0%. The total stretching from the coagulation bath outlet to winding was 6%. The obtained hollow fiber membrane had an inner diameter of 185 μm and a film thickness of 16 μm. The obtained hollow fiber membranes were bundled and inserted into a case, and both ends were bonded and fixed with polyurethane, and modules having an effective area of 1.5 m 2 based on the hollow fiber membrane inner diameter standard were prepared for various evaluations. The evaluation results are summarized in Table 2.
(比較例1)
セルローストリアセテート(6%粘度=162mPa・s、ダイセル化学工業社製)17重量%、N−メチルピロリドン(NMP、三菱化学社製)58.1重量%、トリエチレングリコール(TEG、三井化学社製)24.9重量%を均一に溶解したものを製膜原液として、スリット外径270μm、スリット内径200μmの二重管ノズルのスリット部より吐出し、同時に内液として10重量%NMP水溶液を吐出した。その際、内液はブロック中に冷媒を流さず冷却しなかった。また、製膜原液はブロック中に92℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は20mmのエアギャップ部を通過させた後、NMP/TEG/水=63/7/30からなる45℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.15であった。なお、水洗工程は中空糸膜と洗浄水を向流に流す従来法に従った。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は1.0%であった。凝固浴出口から巻き上げまでの総延伸は6%であった。得られた中空糸膜の内径は200μm、膜厚は19μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタン樹脂で接着固定し、中空糸膜内径基準の膜面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
(Comparative Example 1)
Cellulose triacetate (6% viscosity = 162 mPa · s, manufactured by Daicel Chemical Industries) 17% by weight, N-methylpyrrolidone (NMP, manufactured by Mitsubishi Chemical) 58.1% by weight, triethylene glycol (TEG, manufactured by Mitsui Chemicals) A solution obtained by uniformly dissolving 24.9% by weight was discharged as a film-forming stock solution from the slit portion of a double-tube nozzle having a slit outer diameter of 270 μm and a slit inner diameter of 200 μm, and simultaneously a 10% by weight NMP aqueous solution was discharged as the inner liquid. At that time, the internal liquid did not flow through the block and was not cooled. The film-forming stock solution was heated by circulating a heating medium at 92 ° C. in the block.
After the film-forming stock solution discharged from the nozzle passes through an air gap of 20 mm, it is solidified by being guided into a 45 ° C. coagulation bath composed of NMP / TEG / water = 63/7/30, washed with water, and treated with glycerin. After that, it was dried and wound up. The nozzle draft ratio was 1.15. In addition, the water washing process followed the conventional method in which a hollow fiber membrane and washing water are made to flow countercurrently. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 1.0%. The total stretching from the coagulation bath outlet to winding was 6%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 19 μm. The obtained hollow fiber membrane was bundled and inserted into a case, and both ends were bonded and fixed with polyurethane resin, and a module having a hollow fiber membrane inner diameter standard membrane area of 1.5 m 2 was produced and subjected to various evaluations. . The evaluation results are summarized in Table 2.
(比較例2)
セルローストリアセテート(6%粘度=162mPa・s、ダイセル化学工業社製)17重量%、N−メチルピロリドン(三菱化学社製)58.1重量%、トリエチレングリコール(三井化学社製)24.9重量%を均一に溶解したものを製膜原液として、スリット外径400μm、スリット内径250μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はブロック中に冷媒を流さず冷却しなかった。また、製膜原液はブロック中に92℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は20mmのエアギャップ部を通過させた後、NMP/TEG/水=56/14/30からなる45℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.7であった。なお水洗槽は、傾きを2.5度とし、洗浄水が緩やかに下っていくように調整し、洗浄水を中空糸膜と同じ並流に流した。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は0%であった。凝固浴出口から巻き上げまでの総延伸は4%であった。得られた中空糸膜の内径は200μm、膜厚は18μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタン樹脂で接着固定し、中空糸膜内径基準の膜面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
(Comparative Example 2)
Cellulose triacetate (6% viscosity = 162 mPa · s, manufactured by Daicel Chemical Industries) 17% by weight, N-methylpyrrolidone (Mitsubishi Chemical) 58.1% by weight, triethylene glycol (Mitsui Chemicals) 24.9% % As a film-forming stock solution was discharged from the slit portion of a double-tube nozzle having a slit outer diameter of 400 μm and a slit inner diameter of 250 μm, and water was simultaneously discharged as the inner liquid. At that time, the internal liquid did not flow through the block and was not cooled. The film-forming stock solution was heated by circulating a heating medium at 92 ° C. in the block.
The film-forming stock solution discharged from the nozzle is allowed to pass through a 20 mm air gap, and is then solidified by being guided into a 45 ° C. coagulation bath consisting of NMP / TEG / water = 56/14/30, followed by washing with water and glycerin adhesion treatment. After that, it was dried and wound up. The nozzle draft ratio was 1.7. The washing tank was adjusted to have an inclination of 2.5 degrees so that the washing water gradually descended, and the washing water was allowed to flow in the same co-current as the hollow fiber membrane. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 0%. The total stretching from the coagulation bath outlet to winding was 4%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 18 μm. The obtained hollow fiber membrane was bundled and inserted into a case, and both ends were bonded and fixed with polyurethane resin, and a module having a hollow fiber membrane inner diameter standard membrane area of 1.5 m 2 was produced and subjected to various evaluations. . The evaluation results are summarized in Table 2.
(比較例3)
セルローストリアセテート(6%粘度=162mPa・s、ダイセル化学工業社製)18重量%、N−メチルピロリドン(三菱化学社製)65.6重量%、トリエチレングリコール(三井化学社製)16.4重量%を均一に溶解したものを製膜原液として、スリット外径400μm、スリット内径250μmの二重管ノズルのスリット部より吐出し、同時に内液として水を吐出した。その際、内液はノズルブロック中に0℃の冷媒を流し冷却した。また、製膜原液はブロック中に80℃の熱媒を循環し加熱した。
ノズルから吐出された製膜原液は80mmのエアギャップ部を通過させた後、NMP/TEG/水=57.6/14.4/28からなる45℃の凝固浴中に導いて固化させ、水洗、グリセリン付着処理後、乾燥して巻き取った。ノズルドラフト比は1.4であった。なお、水洗工程は中空糸膜と洗浄水を向流に流す従来法に従った。洗浄水の流速は、0.35m/minに調節、洗浄槽は5段とした。水洗工程における中空糸膜の延伸は1.0%であった。凝固浴出口から巻き上げまでの総延伸は6%であった。得られた中空糸膜の内径は200μm、膜厚は19μmであった。得られた中空糸膜を束状にしてケースに挿入し、両端をポリウレタン樹脂で接着固定し、中空糸膜内径基準の膜面積が1.5m2のモジュールを作製して種々の評価に供した。評価結果を表2にまとめた。
(Comparative Example 3)
Cellulose triacetate (6% viscosity = 162 mPa · s, manufactured by Daicel Chemical Industries) 18% by weight, N-methylpyrrolidone (Mitsubishi Chemical) 65.6% by weight, triethylene glycol (Mitsui Chemicals) 16.4% by weight % As a film-forming stock solution was discharged from the slit portion of a double-tube nozzle having a slit outer diameter of 400 μm and a slit inner diameter of 250 μm, and water was simultaneously discharged as the inner liquid. At that time, the internal liquid was cooled by flowing a 0 ° C. refrigerant through the nozzle block. Moreover, the film-forming stock solution was heated by circulating a heating medium at 80 ° C. in the block.
The film-forming stock solution discharged from the nozzle is passed through an air gap of 80 mm, and then guided into a 45 ° C. coagulation bath consisting of NMP / TEG / water = 57.6 / 14.4 / 28, solidified, and washed with water. After the glycerin adhesion treatment, it was dried and wound up. The nozzle draft ratio was 1.4. In addition, the water washing process followed the conventional method in which a hollow fiber membrane and washing water are made to flow countercurrently. The flow rate of the washing water was adjusted to 0.35 m / min, and the washing tank was 5 stages. The stretching of the hollow fiber membrane in the water washing step was 1.0%. The total stretching from the coagulation bath outlet to winding was 6%. The resulting hollow fiber membrane had an inner diameter of 200 μm and a film thickness of 19 μm. The obtained hollow fiber membrane was bundled and inserted into a case, and both ends were bonded and fixed with polyurethane resin, and a module having a hollow fiber membrane inner diameter standard membrane area of 1.5 m 2 was produced and subjected to various evaluations. . The evaluation results are summarized in Table 2.
表2から明らかなように、断面(2〜4)の開孔率が適正範囲にある実施例1〜6は、性能の安定性や分画性が良好であるだけでなく、強伸度が高いのでモジュール作製の歩留まりが良好である。これに対して、断面開孔率が適正範囲を外れる比較例1〜3は、性能の経時安定性が低く、タンパクリーク量が多いとか、ろ過性能が低いなどの問題が生じている。また、比較例1〜3においては、中空糸膜の強伸度が低いため、モジュール作製の歩留まりが低い。 As is clear from Table 2, Examples 1 to 6 in which the open area ratios of the cross sections (2 to 4) are in an appropriate range not only have good performance stability and good fractionability, but also have high elongation. Since it is high, the module manufacturing yield is good. On the other hand, Comparative Examples 1 to 3 in which the cross-sectional area ratio is outside the proper range have problems such as low performance stability over time, a large amount of protein leak, and low filtration performance. In Comparative Examples 1 to 3, the yield of module production is low because the high elongation of the hollow fiber membrane is low.
本発明の中空糸膜は、少なくとも内表面側に緻密層を有する、いわゆる非対称構造膜であるが、膜断面中間部を均質構造に近い構造とし、また内表面の平滑性や開孔率を適正化したことによって、非常に薄膜でありながら中空糸膜の強度や溶質除去の安定性、有用タンパクの漏出の抑制を高い次元で両立している。そのため血液透析だけでなく血液透析ろ過や血液ろ過にも好適に使用でき、産業の発展に寄与することが大である。 The hollow fiber membrane of the present invention is a so-called asymmetric structure membrane having a dense layer at least on the inner surface side. However, the intermediate portion of the membrane has a structure close to a homogeneous structure, and the inner surface is smooth and has an appropriate porosity. As a result, the strength of the hollow fiber membrane, the stability of solute removal, and the suppression of leakage of useful proteins are compatible at a high level even though it is a very thin film. Therefore, it can be suitably used not only for hemodialysis but also for hemodiafiltration and blood filtration, and contributes to industrial development.
Claims (4)
(a)内表面における300nm以上の孔の存在率が0.5%以下であること、
(b)中空糸膜の断面において、内表面から膜厚の20%までの領域の開孔率が0.1〜5%、外表面から膜厚の20%までの領域の開孔率が22〜30%、それ以外の中間部の領域の開孔率が10〜20%であること、
中空糸膜を用いて内径基準による膜面積が1.5m 2 のモジュールを作製すると、血液流路側にヒトβ2MG(分子量18,000)を0.05〜0.1mg/lの濃度になるように添加した総タンパク質濃度が6.5±0.5g/dl、37℃に保温したACD添加牛血漿を流量200ml/min、透析液側に透析液を500ml/min、ろ過流量15ml/minで流した際に、透析開始後60分時点および240分時点のβ2MGのクリアランスが65ml/min以上であること、及び
内表面から外表面に向かって当初開孔率が増大し、そのまま中間部を過ぎて外表面近傍まで開孔率がほぼ一定で推移し、外表面付近で再度開孔率が増大するような構造を有すること
を特徴とする中空糸膜。 A hollow fiber membrane having an asymmetric structure made of a cellulose acetate polymer, when the hollow fiber membrane is observed at a magnification of 10,000 times using a scanning electron microscope,
(A) The presence rate of pores of 300 nm or more on the inner surface is 0.5% or less ,
(B) In the cross section of the hollow fiber membrane, the porosity of the region from the inner surface to 20% of the film thickness is 0.1 to 5%, and the porosity of the region from the outer surface to 20% of the film thickness is 22 ~ 30%, the porosity of the other intermediate region is 10-20%,
When a module having a membrane area of 1.5 m 2 based on the inner diameter standard is produced using a hollow fiber membrane , human β2MG (molecular weight 18,000) is adjusted to a concentration of 0.05 to 0.1 mg / l on the blood channel side. The total protein concentration added was 6.5 ± 0.5 g / dl, ACD-added bovine plasma kept at 37 ° C. was flowed at a flow rate of 200 ml / min, dialysate was flowed to the dialysate side at 500 ml / min, and the filtration flow rate was 15 ml / min. The clearance of β2MG at the time of 60 minutes and 240 minutes after the start of dialysis is 65 ml / min or more, and
A structure in which the initial hole area ratio increases from the inner surface toward the outer surface, the hole area ratio remains almost constant from the middle part to the vicinity of the outer surface, and the hole area ratio increases again near the outer surface. the hollow fiber membrane according to claim <br/> to have.
(a)製膜原液が、セルロースアセテート系ポリマー、前記ポリマーの溶剤および非溶剤からなること、
(b)内液の水の含有量が95重量%以上100重量%以下であること、
(c)ノズル部での製膜原液の温度が70℃以上110℃以下、内液の温度が0℃以上40℃以下であること、
(d)凝固浴の溶剤濃度が40重量%以上60重量%以下であること、
(e)ノズルドラフト比が0.9〜1.3であること、
(f)ノズルのスリット外径が220〜330μm、スリット内径が150〜270μmであること、
を特徴とする方法。 In the method for producing a hollow fiber membrane according to any one of claims 1 to 3, comprising a step of solidifying in a coagulation bath after passing through the air gap after discharging the membrane-forming stock solution and the internal solution from the double tubular nozzle.
(A) The film-forming stock solution comprises a cellulose acetate polymer, a solvent of the polymer and a non-solvent,
(B) The content of water in the internal solution is 95% by weight or more and 100% by weight or less,
(C) The temperature of the film-forming stock solution at the nozzle part is 70 ° C. or higher and 110 ° C. or lower, and the temperature of the internal solution is 0 ° C. or higher and 40 ° C. or lower,
(D) the solvent concentration of the coagulation bath is 40 wt% or more and 60 wt% or less;
(E) the nozzle draft ratio is 0.9 to 1.3;
(F) The nozzle slit outer diameter is 220 to 330 μm, and the slit inner diameter is 150 to 270 μm.
A method characterized by.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009233985A JP5212837B2 (en) | 2009-10-08 | 2009-10-08 | Permselective hollow fiber membrane |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009233985A JP5212837B2 (en) | 2009-10-08 | 2009-10-08 | Permselective hollow fiber membrane |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011078920A JP2011078920A (en) | 2011-04-21 |
JP5212837B2 true JP5212837B2 (en) | 2013-06-19 |
Family
ID=44073562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009233985A Active JP5212837B2 (en) | 2009-10-08 | 2009-10-08 | Permselective hollow fiber membrane |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5212837B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022092067A1 (en) | 2020-10-30 | 2022-05-05 | 東洋紡株式会社 | Cell cryopreservation hollow fiber membrane |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102140264B1 (en) | 2013-12-20 | 2020-07-31 | 주식회사 엘지화학 | Hollow fiber membrane |
JPWO2018021545A1 (en) * | 2016-07-29 | 2019-05-23 | 東レ株式会社 | Separation membrane and method for producing the same |
EP3533515A4 (en) | 2016-10-31 | 2020-06-24 | Toyobo Co., Ltd. | Cellulose acetate based hollow fiber membrane |
WO2018079807A1 (en) | 2016-10-31 | 2018-05-03 | 東洋紡株式会社 | Cellulose acetate-type asymmetric hollow fiber membrane |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2948856B2 (en) * | 1990-03-19 | 1999-09-13 | 株式会社クラレ | Porous hollow fiber membrane |
JP3228758B2 (en) * | 1997-02-07 | 2001-11-12 | 旭メディカル株式会社 | Hollow fiber membrane and method for producing the same |
JP2000107577A (en) * | 1998-10-08 | 2000-04-18 | Teijin Ltd | Production of permselective hollow fiber membranes |
JP4940576B2 (en) * | 2005-06-10 | 2012-05-30 | 東洋紡績株式会社 | Hollow fiber membrane and blood purifier |
JP4725524B2 (en) * | 2007-01-25 | 2011-07-13 | 東洋紡績株式会社 | Cellulose acetate asymmetric hollow fiber membrane |
-
2009
- 2009-10-08 JP JP2009233985A patent/JP5212837B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022092067A1 (en) | 2020-10-30 | 2022-05-05 | 東洋紡株式会社 | Cell cryopreservation hollow fiber membrane |
Also Published As
Publication number | Publication date |
---|---|
JP2011078920A (en) | 2011-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0294737B1 (en) | Polysulfone hollow fiber membrane and process for making the same | |
JP5440332B2 (en) | Hollow fiber membrane | |
JP5211071B2 (en) | Porous hollow fiber membrane for blood treatment | |
US9149770B2 (en) | Hollow fiber capillary membrane and method for the production thereof | |
JPH06205954A (en) | New high flux hollow fiber membrane | |
WO2007102528A1 (en) | Hollow fiber membrane with excellent performance stability and blood purifier and method for producing hollow fiber membrane | |
JP4725524B2 (en) | Cellulose acetate asymmetric hollow fiber membrane | |
JP5212837B2 (en) | Permselective hollow fiber membrane | |
US10888823B2 (en) | Membrane with improved permeability and selectivity | |
JPH10108907A (en) | Membrane for hemocatharsis, its preparation and module for hemocatharsis | |
JP2792556B2 (en) | Blood purification module, blood purification membrane and method for producing the same | |
JP5217238B2 (en) | Porous hollow fiber membrane and blood purifier excellent in permeation performance stability | |
JP4940576B2 (en) | Hollow fiber membrane and blood purifier | |
JP5471790B2 (en) | Hollow fiber membrane | |
JP5292762B2 (en) | Blood purifier with excellent mass replacement characteristics | |
JP2703266B2 (en) | Polysulfone hollow fiber membrane and method for producing the same | |
JP3212313B2 (en) | Hollow fiber blood purification membrane and method for producing the same | |
JP2008246402A (en) | Hollow fiber type blood purification membrane and method of manufacturing the same | |
JP4029312B2 (en) | Permselective hollow fiber membrane | |
JPH1066725A (en) | Selective-permeability hollow fiber membrane | |
JP6699750B2 (en) | Cellulose acetate-based asymmetric hollow fiber membrane | |
JP4093134B2 (en) | Hollow fiber blood purification membrane | |
JP5578210B2 (en) | Method for producing porous hollow fiber membrane | |
JP5614470B2 (en) | Blood purifier with excellent mass replacement characteristics | |
JP2003275300A (en) | Regenerated cellulose hollow fiber membrane for blood purification, its manufacturing method, and blood purifying apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120702 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130214 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 5212837 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160308 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |